UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.)
Filed by the Registrant [X] Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
[ ] 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to ss.240.14a-12
Synopsys, Inc.
--------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
1) Title of each class of securities to which transaction applies:
--------------------------------------------------------------------------------
2) Aggregate number of securities to which transaction applies:
--------------------------------------------------------------------------------
3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it
was determined):
The Fee is calculated at 1/50th of one percent of $
--------------------------------------------------------------------------------
4) Proposed maximum aggregate value of transaction:
--------------------------------------------------------------------------------
5) Total fee paid:
--------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
--------------------------------------------------------------------------------
2) Form, Schedule or Registration Statement No.:
--------------------------------------------------------------------------------
3) Filing Party:
--------------------------------------------------------------------------------
4) Date Filed:
--------------------------------------------------------------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
June 20, 2003
----------------
To the Stockholders of Synopsys, Inc.:
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Synopsys,
Inc., a Delaware corporation (the "Company"), will be held on June 20, 2003, at
4:00 p.m., local time, in the Babbage conference room of our offices located at
455 N. Mary Avenue, Sunnyvale, California 94085, for the following purposes:
1. To elect nine directors to serve for the ensuing year or until their
successors are elected.
2. To approve an amendment to the Company's Employee Stock Purchase
Plan and International Employee Stock Purchase Plan to increase the
number of shares of Common Stock reserved for issuance thereunder by
1,800,000 shares.
3. To ratify the appointment of KPMG LLP as our independent auditors
for fiscal 2003.
4. To transact such other business as may properly come before the
meeting or any adjournment or adjournments thereof.
The foregoing items of business are more fully described in the Proxy
Statement accompanying this Notice.
Only stockholders of record at the close of business on May 7, 2003 are
entitled to notice of and to vote at the meeting. All stockholders are cordially
invited to attend the meeting in person. However, to assure your representation
at the meeting, you are urged to sign and return the enclosed proxy as promptly
as possible in the envelope enclosed. Any stockholder attending the meeting may
vote in person even if he or she has previously returned a proxy.
Sincerely,
/s/ Aart J. de Geus
Aart J. de Geus
Chief Executive Officer &
Chairman of the Board
Mountain View, California
May 9, 2003
--------------------------------------------------------------------------------
YOUR VOTE IS VERY IMPORTANT, REGARDLESS OF THE NUMBER OF SHARES YOU OWN. PLEASE
READ THE ATTACHED PROXY STATEMENT CAREFULLY, AND COMPLETE, SIGN AND DATE THE
ENCLOSED PROXY CARD AS PROMPTLY AS POSSIBLE AND RETURN IT IN THE ENCLOSED
ENVELOPE.
--------------------------------------------------------------------------------
1
700 East Middlefield Road
Mountain View, California 94043
----------------
PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
To Be Held on June 20, 2003
----------------
GENERAL INFORMATION
The enclosed proxy is solicited on behalf of the Board of Directors of
Synopsys, Inc., a Delaware corporation (referred to in this document as
"Synopsys" or the "Company"), for use at the Annual Meeting of Stockholders to
be held on June 20, 2003, at 4:00 p.m., local time, in the Babbage conference
room of our offices located at 455 N. Mary Avenue, Sunnyvale, California 94085.
These proxy solicitation materials were mailed on or about May 9, 2003 to
all stockholders entitled to vote at the Annual Meeting.
Solicitation
Synopsys will bear the cost of soliciting proxies. We have retained D.F.
King & Co., Inc. to assist us in the solicitation of proxies, for which we will
pay D.F. King & Co. a fee of approximately $8,500 plus out-of-pocket expenses.
We will also reimburse brokerage houses and other persons representing
beneficial owners of shares for their expenses in forwarding solicitation
material to such beneficial owners. We will furnish copies of solicitation
material to such brokerage houses and other representatives. Proxies may also be
solicited by our directors, officers and employees, without additional
compensation, personally or by telephone, telecopy or telegram. Except as
described above, Synopsys does not presently intend to solicit proxies other
than by mail.
Revocability of Proxies
Any person giving a proxy has the power to revoke it at any time before its
use by delivering to Synopsys' principal executive offices a written notice of
revocation or a duly executed proxy bearing a later date. The proxy may also be
revoked by attending the Annual Meeting and voting in person.
Record Date, Voting and Share Ownership
Stockholders of record on May 7, 2003 are entitled to notice of and to vote
at the Annual Meeting. As of the record date, 74,066,198 shares of our common
stock, $.01 par value, were issued and outstanding. No shares of Synopsys'
preferred stock were outstanding.
Each stockholder is entitled to one vote for each share of common stock held
by such stockholder of record as of the close of business on May 7, 2003. The
holders of a majority of the shares issued and outstanding, represented in
person or by proxy, shall constitute a quorum. All valid proxies received before
the meeting will be exercised. All shares represented by a proxy will be voted,
and where a stockholder specifies by means of his or her proxy a choice with
respect to any matter to be acted upon, the shares will be voted in accordance
with the specification so made. If no choice is indicated on the proxy as to a
given proposal, the shares will be voted in favor of the proposal. A stockholder
who abstains on any or all matters will be deemed present at the meeting for
purposes of determining whether a quorum is present and the total number of
votes cast with respect to a proposal (other than votes cast for the election of
directors), but will be deemed not to have voted for or against the particular
matter (or matters) as to which the stockholder has abstained. If a nominee
(such as a brokerage firm) holding shares for a beneficial owner does not
receive instructions from such beneficial owner as to how to vote those shares
on a proposal and does not have discretionary authority to vote on such
proposal, then the shares held by the nominee will be deemed present at the
meeting for quorum purposes but will not be deemed to have voted on such
proposal.
2
MATTERS TO BE CONSIDERED AT ANNUAL MEETING
PROPOSAL ONE -- ELECTION OF DIRECTORS
Synopsys' Bylaws provide that the Board of Directors shall consist of not
fewer than five and not more than nine persons; the Board has set the number of
directors at nine persons. At the Annual Meeting, nine directors are to be
elected to serve until Synopsys' next Annual Meeting or until their successors
are elected and qualified. The Corporate Governance Committee of the Board has
selected nine nominees for director. Each person nominated for election has
agreed to serve if elected, and management has no reason to believe that any
nominee will be unavailable to serve. Unless otherwise instructed, the proxy
holders will vote the proxies received by them FOR the nominees named below. The
nine candidates receiving the highest number of affirmative votes of the shares
represented and voting on this proposal at the Annual Meeting will be elected
directors of Synopsys.
The Board of Directors recommends that the stockholders vote FOR the
election of each of the following nominees to serve as directors of Synopsys
until the next Annual Meeting or until their successors have been elected and
qualified.
Nominees
Set forth below is information regarding the nominees, including information
furnished by them as to principal occupations, certain other directorships held
by them, any arrangements pursuant to which they were selected as directors or
nominees and their ages as of March 31, 2003.
Year First
Name Age Elected Director
---- ---- ----------------
Aart J. de Geus............................ 48 1986
Andy D. Bryant............................. 52 1999
Chi-Foon Chan.............................. 53 1998
Bruce R. Chizen............................ 47 2001
Deborah A. Coleman......................... 50 1995
A. Richard Newton.......................... 51 1987; 1995
Sasson Somekh.............................. 57 1999
Roy Vallee................................. 50 2003
Steven C. Walske........................... 51 1991
Background of Directors
Dr. Aart J. de Geus co-founded Synopsys and currently serves as Chief
Executive Officer and Chairman of the Board of Directors. Since the inception of
Synopsys in December 1986, he has held a variety of positions, including Senior
Vice President of Engineering and Senior Vice President of Marketing. From 1986
to 1992, Dr. de Geus served as Chairman of the Board. He served as President
from 1992 to 1998. Dr. de Geus has served as Chief Executive Officer since
January 1994 and has held the additional title of Chairman of the Board since
February 1998. He has served as a Director since 1986. From 1982 to 1986 Dr. de
Geus was employed by General Electric Corporation, where he was the Manager of
the Advanced Computer-Aided Engineering Group. Dr. de Geus holds an M.S.E.E.
from the Swiss Federal Institute of Technology in Lausanne, Switzerland and a
Ph.D. in electrical engineering from Southern Methodist University.
Andy D. Bryant has been a Director of Synopsys since January 1999 and
currently serves as Executive Vice President and Chief Financial and Enterprise
Services Officer of Intel Corporation, with responsibility for financial
operations, human resources, information technology and e-business functions and
activities worldwide. Mr. Bryant joined Intel in 1981 as Controller for the
Commercial Memory Systems Operation and in 1983 became Systems Group Controller.
In 1987 he was promoted to Director of Finance for the corporation and was
appointed Vice President and Director of Finance of the Intel Products Group in
1990. Mr. Bryant became CFO in February of 1994 and was promoted to Senior Vice
President in January 1999. Mr. Bryant was appointed Chief Financial and
Enterprise Services Officer in December 1999 and was promoted to Executive Vice
President in January 2001. Prior to joining Intel, he held positions in finance
at Ford Motor Company and Chrysler Corporation. Mr. Bryant holds a B.A. in
economics from the University of Missouri and an M.B.A. in finance from the
University of Kansas.
3
Dr. Chi-Foon Chan joined Synopsys as Vice President of Application
Engineering & Services in May 1990. Since April 1997 he has served as Chief
Operating Officer and since February 1998 he has held the additional title of
President. Dr. Chan also became a Director of Synopsys in February 1998. From
September 1996 to February 1998 he served as Executive Vice President, Office of
the President. From February 1994 until April 1997 he served as Senior Vice
President, Design Tools Group and from October 1996 until April 1997 as Acting
Senior Vice President, Design Re-Use Group. Additionally, he has held the titles
of Vice President, Engineering and General Manager, DesignWare Operations and
Senior Vice President, Worldwide Field Organization. From March 1987 to May
1990, Dr. Chan was employed by NEC Electronics, where his last position was
General Manager, Microprocessor Division. From 1977 to 1987, Dr. Chan held a
number of senior engineering positions at Intel Corporation. Dr. Chan holds an
M.S. and Ph.D. in computer engineering from Case Western Reserve University.
Bruce R. Chizen has been a Director of Synopsys since April 2001. Mr. Chizen
has served as President of Adobe Systems Incorporated, a provider of graphic
design, publishing, and imaging software for Web and print production, since
April 2000 and as Chief Executive Officer since December 2000. He joined Adobe
Systems in August 1994 as Vice President and General Manager, Consumer Products
Division and in December 1997 became Senior Vice President and General Manager,
Graphics Products Division. In August 1998, Mr. Chizen was promoted to Executive
Vice President, Products and Marketing. From November 1992 to February 1994 he
was Vice President and General Manager, Claris Clear Choice for Claris Corp., a
wholly-owned subsidiary of Apple Computer. He is a director of Adobe Systems.
Deborah A. Coleman has been a Director of Synopsys since November 1995. Ms.
Coleman is co-founder and currently General Partner of SmartForest Ventures in
Portland, Oregon. Ms. Coleman was Chairman of the Board of Merix Corporation, a
manufacturer of printed circuit boards, from May 1994, when it was spun off from
Tektronix, Inc., until September 2001. She also served as Chief Executive
Officer of Merix from May 1994 to September 1999 and as President from March
1997 to September 1999. Ms. Coleman joined Merix from Tektronix, a diversified
electronics corporation, where she served as Vice President of Materials
Operations, responsible for worldwide procurement, distribution, component
engineering and component manufacturing operations. Prior to joining Tektronix
in November 1992, Ms. Coleman was with Apple Computer, Inc. for eleven years,
where she held several executive positions, including Chief Financial Officer,
Chief Information Officer and Vice President of Operations. She is a director of
Applied Materials, Inc., a manufacturer of semiconductor fabrication equipment,
Chairman of the Board of Teseda Corporation, a semiconductor test equipment
company, and a director of Finatus, Inc., a web-based compliance service
provider.
Dr. A. Richard Newton has been a Director of Synopsys since January 1995.
Previously, Dr. Newton was a Director of Synopsys from January 1987 to June
1991. Dr. Newton has been a Professor of Electrical Engineering and Computer
Sciences at the University of California at Berkeley since 1979 and is currently
Dean of the College of Engineering. From July 1999 to June 2000, Dr. Newton was
Chair of the Electrical Engineering and Computer Sciences Department. Since 1988
Dr. Newton has acted as a Venture Partner with Mayfield Fund, a venture capital
partnership, and has contributed to the evaluation and development of over two
dozen new companies. From November 1994 to July 1995 he was acting President and
Chief Executive Officer of Silicon Light Machines, a private company that has
developed display systems based on the application of micromachined silicon
light-valves.
Dr. Sasson Somekh has been a Director of Synopsys since January 1999. Dr.
Somekh is Executive Vice President of Applied Materials, Inc., a manufacturer of
semiconductor fabrication equipment. Dr. Somekh served as Senior Vice President
from December 1993 to November 2000, and as Group Vice President from 1990 to
1993. Dr. Somekh joined Applied Materials in 1980 as a Project Manager.
Roy Vallee has been a Director of Synopsys since February 2003. Mr. Vallee
is Chief Executive Officer and Chairman of the Board of Avnet, Inc., a global
semiconductor products and electronics distributor, positions he has held since
June 1998. Previously, he was Vice Chairman of the Board since November 1992,
and also President and Chief Operating Officer since March 1992. Mr. Vallee
currently serves on the Board of Directors of Teradyne, Inc., an automated
testing company for the electronics, communications and software industries. He
is also a member of the Executive Committee of the Global Technology
Distribution Council.
Steven C. Walske has been a Director of Synopsys since December 1991. Mr.
Walske has been Chief Business Strategist of Parametric Technology Corporation,
a supplier of software products for mechanical computer aided engineering since
June 2000. Previously, Mr. Walske served as Chairman, Chief Executive Officer
and a Director from August 1994 until June 2000 and as President and Chief
Executive Officer of that company from December 1986 to August 1994.
There are no family relationships among any executive officers, directors or
persons chosen or nominated to become executive officers or directors of
Synopsys.
4
Board Committees and Meetings
Synopsys has a fiscal year that ends on the Saturday nearest October 31 each
year. Synopsys' 2002 fiscal year ended on November 2, 2002 and is referred to in
this document as "fiscal 2002."
During fiscal 2002, the Board of Directors held six meetings. During such
year, the committees of the Board of Directors included an Audit Committee, a
Human Resources and Compensation Committee (the "Compensation Committee") and a
Corporate Governance Committee.
During fiscal 2002, the Audit Committee held ten meetings and consisted of
three directors: Mr. Bryant, Ms. Coleman, and Dr. Somekh. All such directors
served on the Audit Committee for the entire fiscal year. In February 2003, Mr.
Vallee was appointed to the Audit Committee, replacing Mr. Bryant. The Audit
Committee is appointed by the Board to assist the Board in fulfilling its
financial oversight responsibilities relating to (i) the Company's financial
statements, financial reporting processes and systems of internal accounting and
financial controls, (ii) supervising the Company's internal audit function,
(iii) the appointment and evaluation of the Company's independent auditors'
performance and independence and (iv) compliance with legal and regulatory
requirements. A full statement of the Audit Committee's responsibilities and
duties is contained in the Audit Committee Charter, included in this Proxy
Statement as Appendix A.
During fiscal 2002, the Compensation Committee held four meetings and
consisted of four directors: Mr. Bryant, Mr. Chizen, Ms. Coleman and Mr. Walske.
All such directors served on the Committee for the entire fiscal year. The
Compensation Committee is primarily responsible for reviewing and approving
Synopsys' general compensation policies, setting compensation levels for
Synopsys' executive officers and administering Synopsys' stock option, employee
stock purchase and 401(k) savings plans. In March 2000, the Compensation
Committee established a Grant Subcommittee comprised of Committee members Mr.
Chizen, Ms. Coleman and Mr. Walske. The purpose of the Grant Subcommittee is to
ensure that option grants made to executive officers of Synopsys comply with
certain securities and tax rules.
During fiscal 2002, the Corporate Governance Committee held two meetings and
consisted of Mr. Bryant, Mr. Chizen, Ms. Coleman, Dr. Newton, Dr. Somekh and Mr.
Walske, all non-employee directors. All such directors served on the Corporate
Governance Committee for the entire fiscal year. Mr. Vallee was appointed to the
Committee in February 2003. The Corporate Governance Committee identifies and
recommends to the Board candidates for membership on the Board and Board
committees, oversees matters of corporate governance, reviews the performance of
the chief executive officer and other senior executives and reviews such other
matters relating to Synopsys' management as it deems appropriate. The
identification and nomination of Mr. Vallee to the Board of Directors was
coordinated by the Committee. The nominees for election to the Board at the
Annual Meeting were approved by the Committee.
During fiscal 2002, all directors attended at least 75% of the meetings of
the Board of Directors and committees of the Board on which they served, except
that Dr. Somekh attended 70% of the Audit Committee meetings held during such
fiscal year.
Directors' Compensation
Each member of the Board receives a retainer of $25,000 per year for
attendance at Board meetings. Each member of the Audit Committee also receives
$2,000 per Audit Committee meeting attended, other than the Chairperson, who
receives $4,000 per Audit Committee meeting attended, in each case up to maximum
of four meetings per year.
In addition, non-employee members of the Board of Directors receive
automatic option grants under the 1994 Non-Employee Directors Stock Option Plan,
which in this document we refer to as the "Directors Plan." As of the date of
this Proxy Statement, all seven non-employee members of the Synopsys Board of
Directors were eligible to participate in the Directors Plan. Under the
Directors Plan, new directors receive an option for 20,000 shares, vesting in
equal installments over four years assuming continued service through such
dates. In addition, each continuing director who is elected at an annual meeting
of stockholders receives an option for 10,000 shares and an additional option
for 5,000 shares for each Board committee membership, up to a maximum of two
additional options per year. The annual and committee service option grants vest
in full on the date immediately prior to the date of the annual meeting of
stockholders following their grant, assuming continued service through such
date. In the case of directors appointed to the Board between annual meetings,
the annual and any committee grants are prorated based upon the amount of time
since the last annual meeting.
5
During fiscal 2002, Ms. Coleman, Drs. Newton and Somekh and Messrs. Bryant,
Chizen and Walske each received automatic grants of options to purchase 10,000
Synopsys common shares at an exercise price of $49.83 per share for Synopsys
Board of Directors service during the year. In addition, during fiscal 2002,
each of such directors received options to purchase 10,000 Synopsys common
shares for service on Synopsys Board of Directors committees at an exercise
price of $49.83. Mr. Vallee, who joined the Board in February 2003, received an
option for 20,000 shares at an exercise price of $40.92 for his initial service,
a pro-rated annual grant of 3,333 shares at an exercise price of $40.92 per
share and two pro-rated committee grants for an aggregate of 3,333 shares at an
exercise price of $40.46 per share.
During fiscal 2002, Dr. Newton provided consulting services to Synopsys, for
which he was paid $180,000. Under Synopsys' agreement with Dr. Newton, at
Synopsys' request, Dr. Newton provides advice concerning long-term technology
strategy and industry development issues, as well as assistance in identifying
opportunities for partnerships with academia.
Intel Corporation, of which Mr. Bryant serves as Senior Vice President and
Chief Financial and Enterprise Services Officer, accounted for more than five
percent of Synopsys' total revenue during fiscal 2002. Synopsys' management
believes the transactions between the two parties were carried out on an
arm's-length basis.
6
Security Ownership of Certain Beneficial Owners and Management
The following table sets forth certain information with respect to the
beneficial ownership of Synopsys common shares as of March 31, 2003 by (1) each
person known by Synopsys to own beneficially more than five percent of Synopsys'
common shares outstanding on that date, (2) each Synopsys director, (3) each of
the named executive officers (as defined below under "Executive Compensation")
and (4) all Synopsys directors and current executive officers as a group.
Shares of Common Stock
Beneficially Owned
Percentage
Name of Beneficial Owner(1) Number Ownership
----------------------------- ------- ----------
J. & W. Seligman & Co. Inc................ 7,776,496(2) 10.46%
100 Park Avenue, 8th Floor
New York, NY 10017
Franklin Resources, Inc................... 5,291,927(3) 7.12%
One Franklin Parkway
San Mateo, CA 94403-1906
Blum Capital Partners, L.P................ 4,906,200(4) 6.60%
909 Montgomery Street, Suite 400
San Francisco, CA 94133-4625
FMR Corp.................................. 4,785,520(5) 6.44%
82 Devonshire Street
Boston, MA 02109
Harris Associates L.P..................... 3,805,900(6) 5.12%
Two North LaSalle Street, Suite 500
Chicago, IL 60602-3790
Vicki L. Andrews.......................... 139,984(7) *
Andy D. Bryant............................ 93,749(8) *
Chi-Foon Chan............................. 970,934(9) 1.31%
Bruce R. Chizen........................... 59,166(10) *
Deborah A. Coleman........................ 60,000(11) *
Aart J. de Geus........................... 1,743,811(12) 2.35%
Robert B. Henske ......................... 0(13) *
A. Richard Newton......................... 95,916(14) *
Steven K. Shevick......................... 136,269(15) *
Sasson Somekh............................. 113,333(16) *
Roy Vallee................................ 26,666(17) *
Steven C. Walske.......................... 116,016(18) *
All directors and current executive....... 3,810,387(19) 5.13%
officers as a group (13 persons)
----------------
* Less than 1%
(1) The persons named in the table above have sole voting and investment
power with respect to all Synopsys common shares shown as beneficially
owned by them, subject to community property laws where applicable and
the information contained in the footnotes of this table.
(2) Share ownership for J. & W. Seligman & Co. Incorporated was obtained
from Amendment No. 11 to the Schedule 13G filed with the Securities and
Exchange Commission on February 11, 2003.
(3) Share ownership for Franklin Resources was obtained from Amendment No. 2
to the Schedule 13D filed with the Securities and Exchange Commission on
February 12, 2003. Includes 2,127,450 shares as to which Franklin
Advisers, Inc. has sole voting power, 1,921,522 shares as to which
Templeton Global Advisers Limited has sole voting power, 448,785 shares
as to which Fiduciary Trust Company International has sole voting power,
411,068 shares as to which Franklin Templeton Investment Management
Limited has sole voting power, 232,110 shares as to which Templeton
Investment Counsel, LLC has sole voting power, 147,817 shares as to which
Franklin Templeton Investments Corp. has sole voting power and 3,175
shares as to which Templeton/Franklin Investment Services, Inc. has sole
voting power.
7
(4) Share ownership for Blum Capital Partners, L.P. was obtained from
Schedule 13F-R filed with the Securities and Exchange Commission on
February 14, 2003.
(5) Share ownership for FMR Corp. was obtained from Amendment No. 2 to the
Schedule 13G filed with the Securities and Exchange Commission on
February 14, 2003.
(6) Share ownership for Harris Associates L.P. was obtained from Schedule 13G
filed with the Securities and Exchange Commission on February 14, 2003.
Includes 1,620,900 shares over which Harris Associates L.P. has sole
voting power and 2,185,000 shares over which Harris Associates L.P. has
shared voting power.
(7) Includes options to purchase 139,090 Synopsys common shares exercisable
by Ms. Andrews within 60 days of March 31, 2003.
(8) Consists of options to purchase 93,749 Synopsys common shares
exercisable by Mr. Bryant within 60 days of March 31, 2003.
(9) Includes options to purchase 938,484 Synopsys common shares exercisable
by Dr. Chan within 60 days of March 31, 2003.
(10) Consists of options to purchase 59,166 Synopsys common shares
exercisable by Mr. Chizen within 60 days March 31, 2003.
(11) Consists of options to purchase 60,000 Synopsys common shares
exercisable by Ms. Coleman within 60 days of March 31, 2003.
(12) Includes options to purchase 1,431,561 Synopsys common shares
exercisable by Dr. de Geus within 60 days of March 31, 2003.
(13) Mr. Henske resigned from his position effective January 3, 2003.
(14) Consists of options to purchase 95,916 Synopsys common shares
exercisable by Dr. Newton within 60 days of March 31, 2003.
(15) Includes options to purchase 133,742 Synopsys common shares exercisable
by Mr. Shevick within 60 days of March 31, 2003.
(16) Includes options to purchase 100,833 Synopsys common shares exercisable
by Dr. Somekh within 60 days of March 31, 2003.
(17) Consists of options to purchase 26,666 Synopsys common shares
exercisable by Mr. Vallee within 60 days of March 31, 2003.
(18) Includes options to purchase 115,916 Synopsys common shares exercisable
by Mr. Walske within 60 days of March 31, 2003.
(19) Includes options to purchase 3,448,546 Synopsys common shares
exercisable by directors and current executive officers within 60 days
of March 31, 2003.
8
Executive Compensation
Executive Compensation and Other Matters
The following table sets forth the compensation earned during fiscal 2002 by
(1) Synopsys' Chief Executive Officer and (2) each of the other four most highly
compensated executive officers whose compensation for fiscal 2002 exceeded
$100,000, whom in this document we collectively refer to as the "named executive
officers," for services rendered in all capacities to Synopsys during the last
three fiscal years.
Summary Compensation Table
Long-Term
Compensation:
Securities
Name and Awards All Other
Position Annual Compensation ($) Underlying Compensation
Year Salary Bonus Options (#) ($) (1)
------ --------- ------- ------------- -------------
Aart J. de Geus..................... 2002 446,154 575,000 106,500 1,500
Chief Executive Officer and 2001 400,000 575,000 85,500 1,830
Chairman of the Board 2000 430,769 600,000 731,000 1,855
Chi-Foon Chan....................... 2002 400,000 575,000 91,700 5,138
President and Chief Operating 2001 400,000 575,000 71,000 2,588
Officer 2000 430,769 600,000 623,000 2,493
Vicki L. Andrews.................... 2002 300,000 448,385(2) 72,900 13,884
Senior Vice President 2001 289,423 611,396(3) 60,500 9,544
World Wide Sales 2000 287,500 568,256(4) 179,000 9,826
Steven K. Shevick(5)................ 2002 250,000 220,000 25,300 1,500
Senior Vice President and 2001 241,538 175,000 17,500 1,871
Chief Financial Officer 2000 236,154 160,984 100,000 1,833
Robert B. Henske.................... 2002(6) 375,000 350,000 73,300 1,500
Former Senior Vice President and 2001 364,423 350,000 60,500 1,825
Chief Financial Officer 2000(7) 175,000 232,000 340,000 160
------------------------
(1) Amounts in this column reflect premiums paid for group term life insurance,
Synopsys 401(k) contributions and, in the case of Ms. Andrews only, car
allowances. Dr. Chan's 2002 amounts include special travel allowance.
(2) Ms. Andrews' 2002 bonus consists of commissions of $102,125 and variable
bonus of $346,260.
(3) Ms. Andrews' 2001 bonus consists of commissions of $150,000, a variable
bonus of $296,260, a relocation bonus of $160,000 and a special bonus of
$5,136.
(4) Ms. Andrews' 2000 bonus consists of commissions of $318,096 and a variable
bonus of $250,160.
(5) Mr. Shevick was appointed Chief Financial Officer of Synopsys on January 2,
2003. Prior to that, he served as Vice President, Investor Relations and
Legal and General Counsel.
(6) Mr. Henske resigned from his position effective January 3, 2003.
(7) Mr. Henske commenced employment with Synopsys on May 10, 2000.
9
Stock Option Grants
The following table sets forth further information regarding individual
grants of options for Synopsys' common stock during fiscal 2002 for each of the
named executive officers. All grants for each of the named executive officers
were made pursuant to Synopsys' 1992 Stock Option Plan (the "1992 Plan"). In
accordance with the rules of the Securities and Exchange Commission (the "SEC"),
the table sets forth the hypothetical gains or "option spreads" that would exist
for the options at the end of their respective ten-year terms based on assumed
annualized rates of compound stock price appreciation of 5% and 10% from the
dates the options were granted to the end of the respective option terms. Actual
gains, if any, on option exercises are dependent on the future performance of
Synopsys common stock and overall market conditions.
Option Grants in Last Fiscal Year
Individual Grants
Number of Percent of Potential Realizable Value at
Securities Total Range of Assumed Annual Rates of Stock
Under-lying Options Exercise Price Appreciation for Option Term
Options Granted to Prices ($)
Name Granted (1) Employees (2) ($/Share) Expiration Date 5% 10%
----------------- ------------- ------------- --------------- ------------------ ----------- -----------
Aart J. de Geus 106,500 2.69% $44.56 - $56.17 12/17/11 - 8/27/12 $ 3,533,394 $ 8,954,315
Chi-Foon Chan 91,700 2.32% $44.56 - $56.17 12/17/11 - 8/27/12 $ 3,028,417 $ 7,674,603
Vicki L. Andrews 72,900 1.84% $44.56 - $56.17 12/17/11 - 8/27/12 $ 2,417,345 $ 6,126,027
Steven K. Shevick 25,300 0.64% $44.56 - $56.17 12/17/11 - 8/27/12 $ 825,997 $ 2,093,239
Robert B. Henske (3) 73,300 1.85% $44.56 - $56.17 12/17/11 - 8/27/12 $ 2,429,772 $ 6,157,520
-------------------------
(1) Sum of all option grants made during fiscal 2002 to such person. Options
become exercisable ratably in a series of monthly installments over a
four-year period from the grant date, assuming continued service to
Synopsys, subject to acceleration under certain circumstances involving a
change in control of Synopsys. Each option has a maximum term of ten years,
subject to earlier termination upon the optionee's cessation of service.
(2) Based on a total of 3,960,661 shares subject to options granted to
employees under Synopsys' option plans during fiscal 2002.
(3) Mr. Henske resigned from his position effective January 3, 2003.
Option Exercises and Year-End Values
The following table sets forth, for each of the named executive officers,
each exercise of stock options during fiscal 2002 and the year-end value of
unexercised options.
No stock appreciation rights were exercised during such fiscal year by the
named executive officers, and no stock appreciation rights were outstanding at
the end of the fiscal year.
Aggregated Option Exercises in Last Fiscal Year and Fiscal Year-End Option Values
Number of Securities
Underlying Unexercised
Shares Options at Fiscal 2002 Value of In-the-Money
Acquired on Value Year-End Options at Fiscal 2002 Year-End (2)
Name Exercise Realized(1) Exercisable/Unexercisable Exercisable/Unexercisable
----------------- ----------- ----------- ------------------------ ------------------------------------
Aart J. de Geus -- -- 1,281,094 447,606 $ 4,659,659 $ 1,236,025
Chi-Foon Chan -- -- 810,462 377,438 $ 1,919,835 $ 945,044
Vicki L. Andrews 50,000 $ 962,700 93,908 172,658 $ 138,782 $ 389,439
Steven K. Shevick 5,000 $ 132,725 109,082 73,218 $ 349,036 $ 163,144
Robert B. Henske(3) -- -- 236,633 237,167 $ 607,275 $ 467,825
-----------------------------------
(1) Market value at exercise, less exercise price.
10
(2) Market value of underlying securities at November 1, 2002 minus the
exercise price. Since fiscal 2002 ended on Saturday, November 2, 2002,
market value is given as of November 1, 2002, the last trading day before
the end of the fiscal year.
(3) Mr. Henske resigned from his position effective January 3, 2003.
Security Holder Approval of Equity Compensation Plans
The following table provides information regarding equity compensation plans
approved and not approved by security holders as of the end of fiscal 2002:
Number of Securities
Remaining Available
Number of Securities Weighted-Average for Future Issuance
to be Issued Upon Exercise Price of Under Equity
Exercise of Outstanding Compensation Plans
Outstanding Options, Options,Warrants, (Excluding Securities
Warrants, and Rights(3) and Rights Reflected in Column 1)
Plan Category
--------------------------------------------------------------------------------------------------------------
Employee Equity Compensation Plans
Approved by Stockholders (1) 6,630,094 $ 40.32 6,480,608
Employee Equity Compensation Plans
Not Approved by Stockholders(2) 18,832,666 $ 42.64 4,817,722
-------------------------------------------------------------
Total 25,462,760 $ 42.04 11,298,330 (4)
(1) Synopsys' stockholder approved equity compensation plans include the 1992
Plan, the Employee Stock Purchase Plans and the Directors Plan.
(2) Synopsys' only non-stockholder approved equity compensation plan is the
1998 Non-Statutory Stock Option Plan (the "1998 Plan")
(3) Does not include information for options assumed in connection with mergers
and acquisitions. As of fiscal 2002 year end, a total of 2,516,779 shares
of our common stock were issuable upon exercise of such outstanding
options.
(4) Comprised of (i) 3,523,486 shares remaining available for grant under the
1992 Plan, (ii) 4,817,722 shares remaining available for issuance under the
1998 Plan, (iii) 2,885,283 shares remaining available for issuance under
the Company's Employee Stock Purchase Plans and (iv) 71,839 shares
remaining available for grant under the Directors Plan, all as of fiscal
2002 year end.
Employment Contracts, Termination of Employment Arrangements and Change of
Control Agreements
Under the 1992 Plan, in the event of certain changes in the ownership or
control of Synopsys involving a "Corporate Transaction," which includes an
acquisition of Synopsys by merger or asset sales, each outstanding option under
the 1992 Plan will automatically become exercisable, unless the option is
assumed by the successor corporation, or parent thereof, or replaced by a
comparable option to purchase shares of the capital stock of the successor
corporation, or parent thereof.
In addition, in the event of a successful hostile tender offer for more than
50% of the outstanding Synopsys common shares or a change in the majority of the
Board of Directors as a result of one or more contested elections for membership
on the Board of Directors, the administrator of the 1992 Plan has the authority
to accelerate vesting of outstanding options or shares purchased under the 1992
Plan.
The Directors Plan provides that in the event of a change of control or
corporate transaction, as such terms are defined in the Directors Plan, all
outstanding Directors Plan options shall become fully vested and exercisable as
of the date of such change of control or corporate transaction.
Synopsys has entered into Employment Agreements, effective October 1, 1997,
with its Chief Executive Officer and its President. Each Employment Agreement
provides that if the executive is terminated involuntarily other than for cause
11
within 24 months of a change of control, (a) the executive will be paid an
amount equal to two times the sum of the executive's annual base pay plus target
cash incentive, plus the cash value of the executive's health benefits for the
next 18 months, and (b) all stock options held by the executive will immediately
vest in full. If the executive is terminated involuntarily other than for cause
in any other situation, the executive will receive a cash payment equal to the
sum of the executive's annual base pay for one year plus the target cash
incentive for such year, plus the cash value of the executive's health benefits
for 12 months. The terms "involuntary termination," "cause" and "change of
control" are defined in the Employment Agreements, each of which is filed with
the SEC.
Report of the Compensation Committee
The following is the report of the Compensation Committee of the Board of
Directors describing the compensation policies, and the rationale therefore,
with respect to the compensation paid to Synopsys' executive officers during
fiscal 2002.
Executive Compensation
Purpose of the Compensation Committee
The Compensation Committee determines compensation levels for the
executive officers for each fiscal year based upon a consistent set of
procedures. The Compensation Committee reviews and approves all executive target
compensation (base and bonus) and the plan by which bonus in excess of target
may be paid to executive officers. In the case of Synopsys' principal sales
executive, the Chief Executive Officer and President, in consultation with the
Compensation Committee, formulate an individual bonus plan based primarily upon
revenues and accepted orders for Synopsys' products and services.
Committee Structure
During fiscal 2002 the Compensation Committee consisted of four
non-employee members of the Board of Directors: Ms. Coleman and Messrs. Bryant,
Chizen, and Walske. The Compensation Committee has established a Grant
Subcommittee comprised of Committee members Mr. Chizen, Ms. Coleman and Mr.
Walske. The purpose of the Grant Subcommittee is to ensure that option grants
made to executive officers of Synopsys comply with certain securities and tax
rules.
Objectives of the Compensation Program
The objectives of the compensation program as established by the
Compensation Committee are: (1) to provide a means for Synopsys to attract and
retain high-quality executives, (2) to tie executive compensation directly to
Synopsys' business and performance objectives and (3) to reward outstanding
individual performance that contributes to Synopsys' long-term success.
Elements of Compensation
Each executive officer's compensation package is comprised of three
elements: (1) base compensation, (2) variable or bonus compensation payable
based on the achievement of the Company's financial performance goals and
individual performance and (3) long-term stock-based incentive compensation,
which rewards Company growth and increased stockholder value.
Base Compensation. The base compensation for each executive officer is
determined based on the following factors: (1) salary levels for comparable
positions in software and related companies similar in size and business that
compete with Synopsys in the recruitment and retention of senior personnel, (2)
each executive's past performance relative to corporate, business group (if
applicable) and individual objectives, (3) each executive's responsibility level
and objectives for the subsequent year and (4) compensation relative to other
executives at Synopsys.
Information regarding competitive salary ranges for fiscal 2002 was obtained
from an independent compensation survey firm. Synopsys uses companies included
in the S&P Information Technology Index for peer compensation information,
excluding certain companies which (i) are larger than Synopsys, (ii) participate
in different industries than Synopsys or (iii) are located in different regions
than Synopsys.
Synopsys believes that the total cash compensation for the executive
officers of Synopsys for fiscal 2002 was competitive with the total cash
compensation for executive officers at comparable companies.
12
Variable Compensation. The Board and Compensation Committee met during the
first quarter of fiscal 2002 to establish the incentive bonus compensation
structure for executive officers for fiscal 2002. Synopsys' fiscal 2002 bonus
plan sets forth (1) the size of the aggregate bonus pool for all executive
officers and non-commissionable employees and (2) the amount of incentive bonus
compensation payable to individual executive officers (other than Synopsys'
principal sales executive) based on the achievement of specific performance
targets relating to accepted orders, revenue and expense levels for Synopsys as
a whole (and, for general managers of business units, orders and expenses for
their individual business units). An executive officer's bonus compensation is
also determined based upon a qualitative assessment of his or her performance by
the Chairman of the Board and Chief Executive Officer and President and Chief
Operating Officer, in consultation with and approval by the Compensation
Committee and the Board of Directors. The bonuses payable to all such executive
officers, together with bonuses payable to all other non-commissionable
employees as a group, may not exceed the total bonus pool approved by the
Compensation Committee.
For fiscal 2002, a bonus formula was established such that achievement of
planned accepted orders, revenue and expense levels, would result in a specified
bonus pool. For performance levels over or under plan, the bonus compensation
pool would increase or decrease. The formula contains an "accelerator" for
performance above the Company's plan; conversely, performance below plan yields
a substantially reduced bonus pool. During the year, the target levels of
orders, revenue and expense levels were adjusted to take into account completion
of the acquisition of Avant! Corporation.
For fiscal 2002, though revenues were at target and expenses were below
target, accepted orders were below target. Accordingly, aggregate bonus
compensation was also below target. Similarly, bonus compensation for Synopsys'
principal sales executive for fiscal 2002 under her individual bonus plan was
below target due to underachievement of orders against the Company's plan for
fiscal 2002. The Summary Compensation Table on page 9 reflects total bonus
compensation for the named executive officers. The Committee believes those
compensation levels fairly reflect the named executive officers' individual
performance.
Long-Term Incentive Compensation. The Company provides long-term
compensation to Synopsys' executives in the form of stock options. The
Compensation Committee believes that equity-based compensation closely aligns
the interests of executive officers with those of stockholders by providing an
incentive to manage Synopsys with a focus on long-term strategic objectives set
by the Board of Directors relating to growth and stockholder value. Stock
options are granted under the 1992 Plan and the 1998 Plan according to
guidelines that take into account the executive's responsibility level,
comparison with comparable awards to individuals in similar positions in the
industry, Synopsys' long-term objectives for maintaining and expanding
technological leadership through product development and growth, expected
Company performance, the executive's performance and contribution during the
last fiscal year and the executive's existing holdings of unvested stock
options. However, the Compensation Committee does not strictly adhere to these
factors in all cases and will vary grants made to each executive officer as the
particular circumstances warrant. Exercise prices for options are set at the
fair market value of Synopsys common stock on the date of grant.
The options vest in a series of installments over a four-year period,
contingent upon the executive's continued employment with Synopsys. Accordingly,
the option will provide a return to the executive only if he or she remains in
Synopsys' employ, and then only if the market price of the Common Stock
appreciates over the option term. Subsequent grants may be made to officers when
the Compensation Committee believes that the officer has demonstrated greater
potential, achieved more than originally expected, or assumed expanded
responsibilities. Additionally, subsequent grants may be made to remain
competitive with similar companies.
The Compensation Committee evaluated the performance of the named executive
officers against the strategic objectives for fiscal 2002 set by the Board and
concluded that such performance warranted the level of long-term compensation
awarded them as set forth in the Summary Compensation Table on page 9. The
Compensation Committee typically reexamines long-term compensation levels each
year.
Chairman of the Board/Chief Executive Officer's Compensation
Compensation for the Chairman/CEO is determined by a process similar to that
discussed above for other executive officers. Dr. de Geus' base compensation for
fiscal 2002 was established by the Compensation Committee in December 2001 and
was the same as his base compensation for fiscal 2001. The Compensation
Committee believes Dr. de Geus' base compensation is competitive with base
compensation levels for chief executive officers of the companies with which
Synopsys competes for executives.
As was the case with the other executive officers, Dr. de Geus' bonus was
calculated under a formula based on accepted orders, revenue and expense levels
and was adjusted based upon actual performance related to plan. Dr. de Geus'
bonus compensation was also determined based on a qualitative assessment of his
performance by the Compensation Committee and Board of Directors. For fiscal
13
2002, although revenues were at target and expenses were below target, accepted
orders were below target. As a result, Dr. de Geus' overall fiscal 2002 bonus
shown in the Summary Compensation Table on page 9 was lower than his target
bonus. In determining the amount of long-term compensation to grant to Dr. de
Geus, the Compensation Committee considered the same factors used to determine
grants for other executive officers set forth above.
The Committee believes that Dr. de Geus' overall level of compensation
fairly reflects his performance for the year.
Tax Deductibility of Executive Compensation
Section 162(m) of the Internal Revenue Code places a $1 million limit on the
tax deductibility of cash compensation paid to our five most highly compensated
executive officers. We expect that a portion of the cash compensation paid to
the Chief Executive Officer in fiscal 2002 will not qualify for a tax deduction
as a result of Section 162(m); the aggregate amount of such nondeductible
compensation is not material to Synopsys. Under the 1992 Plan, compensation
deemed paid to an executive officer when he or she exercises an outstanding
option under the Plan will qualify as performance-based compensation, and is
therefore not subject to the $1 million limitation.
COMPENSATION COMMITTEE
Steven C. Walske, Chairperson
Andy D. Bryant
Bruce R. Chizen
Deborah A. Coleman
14
Committee Interlocks and Insider Participation
No Compensation Committee member was at any time during fiscal 2002, or at
any other time, an officer or employee of Synopsys.
No executive officer of Synopsys serves on the board of directors or
compensation committee of any entity that has one or more executive officers
serving on Synopsys' Board of Directors or Compensation Committee.
Report of the Audit Committee
Other than the information set forth below in "Fees Billed to Synopsys by
KPMG LLP during Fiscal 2002," the following Report of the Audit Committee shall
not constitute "soliciting material" nor shall it be deemed "filed" with the SEC
and is not to be incorporated by reference into any other Company filing under
the Securities Act of 1933 (the "Securities Act") or the Securities Exchange Act
of 1934 (the "Exchange Act"), except to the extent Synopsys specifically
incorporates this Report by reference therein.
Audit Committee Charter
The Charter of the Audit Committee, as amended and approved by the Board of
Directors, is included in this Proxy Statement as Appendix A.
Communications with Management and Independent Accountants
The Audit Committee has reviewed and discussed our audited financial
statements with management. In addition, the Audit Committee has discussed with
KPMG LLP, Synopsys' independent accountants, the matters required to be
discussed by Statement of Auditing Standards No. 61, "Communications With Audit
Committees" which includes, among other items, matters related to the conduct of
the audit of our financial statements. The Audit Committee has also received
written disclosures and the letter from KPMG LLP required by the Independence
Standards Board Standard No. 1, which relates to the accountant's independence
from Synopsys and its related entities, and has discussed their independence
from Synopsys, including whether KPMG LLP's provision of non-audit services was
compatible with that independence.
Committee Member Independence
Committee members Ms. Coleman, Dr. Somekh and Mr. Vallee qualify as
"independent" directors under the current listing standards of the National
Association of Securities Dealers (the "NASD"). Mr. Bryant, who was a member of
the Committee during fiscal 2002, did not qualify as an independent director
under such standards due to the fact that he was an executive officer of a
greater than 5% customer of Synopsys in fiscal 2002. However, in accordance with
NASD listing standards, Synopsys' Board of Directors (with Mr. Bryant
abstaining) determined that Mr. Bryant's membership on the Audit Committee was
in the best interests of Synopsys and its stockholders due to Mr. Bryant's high
level of experience in financial and accounting matters. In February 2003, Mr.
Vallee was appointed to the Audit Committee, replacing Mr. Bryant.
Recommendation Regarding Financial Statements
Based on the review and discussions referred to above, the Audit Committee
recommended to the Board of Directors that the Company's audited financial
statements be included in the Annual Report on Form 10-K for fiscal 2002.
Fees Billed to Synopsys by KPMG LLP during Fiscal 2002
Audit Fees
KPMG LLP's audit fees billed to Synopsys during fiscal 2002 totaled
approximately $3,235,000. This amount is comprised of $2,000,000 in fees for the
annual audit of Synopsys' financial statements included in its Annual Report on
Form 10-K for fiscal 2002, review of the financial statements included in
Synopsys' fiscal 2002 Quarterly Reports on Form 10-Q and foreign statutory
audits, and $1,235,00 in fees for Avant! Corporation acquisition-related audits
and filings.
15
Financial Information Systems Design and Implementation Fees
KPMG LLP did not perform any financial information systems design or
implementation services for Synopsys during fiscal 2002.
All Other Fees
KPMG LLP's fees billed to Synopsys for all other services rendered totaled
approximately $796,000. This amount is comprised of $484,000 in fees for tax
related services and $312,000 for due diligence work related to acquisitions.
AUDIT COMMITTEE
Deborah A. Coleman, Chairperson
Sasson Somekh
Roy Vallee
16
Performance Graph
The following graph compares the cumulative total return to stockholders of
Synopsys' common stock from September 30, 1997 through October 31, 2002 to the
cumulative total return of (1) the S&P 500 Index and (2) the S&P Information
Technology Index (formerly known as the S&P Technology Sector Index) over the
same period (assuming the investment of $100 in Synopsys' common stock and in
each of the other indices, and reinvestment of all dividends). This section
shall not constitute "soliciting material" nor shall it be deemed "filed" with
the SEC, and is not to be incorporated by reference into any other Company
filing under the Securities Act or the Exchange Act, except to the extent
Synopsys specifically incorporates this section therein.
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN
AMONG SYNOPSYS, INC., THE S&P 500 INDEX
AND THE S&P INFORMATION TECHNOLOGY INDEX
[PERFORMANCE GRAPH]
SYNOPSYS, INC. S&P 500 S&P TECHNOLOGY
INDEX INDEX
9/97 100 100 100
9/98 78.38 109.05 113.81
9/99 132.13 139.37 204.30
10/00 82.06 157.21 232.01
10/01 110.59 118.06 105.93
10/02 89.06 100.23 76.10
17
PROPOSAL TWO -- AMENDMENT TO EMPLOYEE
STOCK PURCHASE PLANS
Proposed Amendment
At the Annual Meeting, the Company's stockholders will be asked to approve
an increase in the total number of shares authorized under the Company's
Employee Stock Purchase Plan and International Employee Stock Purchase Plan (the
"Plans") of 1,800,000 shares.
Explanation
The Plans permit employees of the Company and its subsidiaries to purchase
the Company's Common Stock at a discounted price. The Plans are designed to
encourage and assist a broad spectrum of the Company's employees to acquire an
equity interest in the Company through the purchase of Common Stock. The Plans
also are intended to provide to United States employees participating in the
Plans the tax benefits available under Section 423 of the Internal Revenue Code
of 1986, as amended. As of February 28, 2003, the last purchase date under the
Plans, approximately 2,792 of approximately 4,090 eligible employees were
participants in the Plans. As of February 28, 2003, an aggregate of 4,557,217
shares had been issued to employees under the Plans and 2,498,783 shares
remained available for issuance.
Management believes that maintaining a competitive employee stock purchase
program is an important element in recruiting and retaining employees. The Plans
are designed to more closely align the interests of employees and stockholders
by encouraging employees to invest in the Company's securities, and to help
employees share in the Company's success. Further, employee stock purchase plan
gains have become an important part of overall compensation of employees.
The Company is requesting authorization of additional shares under the Plans
in order to preserve the current benefits of the Plans for employees and
favorable accounting treatment for the Company. The Plans currently provide for
enrollment periods of 24-months as described under "Description of Plans." Under
current accounting rules, if (i) at the start of an enrollment period, the
shares reserved for issuance under an employee stock purchase plan are
insufficient to cover all shares issuable throughout that period, (ii) any
shares sold during an enrollment period are authorized after the commencement of
the enrollment period and (iii) on the authorization date the fair market value
("FMV") of the Common Stock is higher than the FMV at the beginning of the
enrollment period, then the Company would be required to record a charge to
earnings, which could be significant, for each subsequent quarter when the FMV
on each semi-annual purchase date during the 24-month enrollment period was
above the FMV on the enrollment date, to reflect the perceived compensatory
element of the difference in FMV.
The Company estimates, based on certain assumptions it considers reasonable,
that enough shares are available under the Plans to cover purchases under the
Plans by all current participants in all current 24-month enrollment periods.
However, the Company believes that, under certain circumstances, it will need
additional shares to cover purchases under the Plans by participants who may
enroll in enrollment periods commencing between the Annual Meeting and the
expected date of the 2004 Annual Meeting. Consequently, the Board of Directors
has adopted, subject to stockholder approval, an amendment to the Plans to
increase the aggregate number of shares issuable under the Plans by 1,800,000
shares in order to avoid any potential charge to earnings caused by a share
shortfall discussed above. The Company believes that the assumptions it has used
in estimating the need for additional shares are reasonable. Some of these
assumptions, however, are based on factors that cannot be precisely predicted,
including the future number of the Company's employees, the future price of the
Company's Common Stock, the Company's overall salary levels and the
participation rate in the Plans.
Approval of the amendment to the Plans requires the affirmative vote of a
majority of the votes cast at a duly held stockholders' meeting at which there
is a quorum.
18
Recommendation
As stated above, the Board of Directors believes that the proposed amendment
to the Plans is important for employee retention and in the best interests of
the Company and of its stockholders. Accordingly, the Board of Directors
recommends a vote FOR approval of the increase in shares issuable under the
Plans.
DESCRIPTION OF PLANS
The following is a summary of the principal features of the Plans. The
summary, however, does not purport to be a complete description of all of the
provisions of the Plans. Any stockholder who wishes to obtain a copy of the
actual plan documents may do so by written request to the Company's Secretary at
the Company's executive offices.
All regular employees, including executive officers and directors who are
employees, customarily employed more than 20 hours per week and more than five
months per year by the Company or a participating subsidiary, are eligible to
participate in the Plans as of the first enrollment date following employment.
Participants may elect to make contributions up to a maximum of 10% of base
earnings. On the last trading date of each semi-annual purchase period, the
Company applies the funds then in each participant's account to the purchase of
shares. The purchase dates are the last trading day of February and August. The
cost of each share purchased is 85% of the lower of the closing prices for the
Company's Common Stock on (i) the first trading day in the enrollment period in
which the purchase is made and (ii) the purchase date. The closing price of the
Company's Common Stock as reported on the Nasdaq National Market on May 5, 2003
was $50.67 per share. The length of each enrollment period may not exceed 24
months. A new six-month offering period within each 24-month enrollment period
commences each March 1 and September 1. Under the Plans, the maximum amount of
payroll deductions by a participant during any semi-annual purchase period is
$7,500, and no participant's right to acquire shares may accrue at a rate
exceeding $25,000 of fair market value of Common Stock (determined as of the
first business day in an enrollment period) in any calendar year. No single
participant may acquire more than 2,000 shares, and all participants may not
acquire more than 500,000 shares in the aggregate, on any semi-annual purchase
date.
The Plans are administered by the Compensation Committee, but routine
matters are delegated to management. The Board of Directors may amend or
terminate the Plans at any time and may adjust the purchase price and the number
and kind of securities available under the Plans in the event of a
reorganization, recapitalization, stock split, or other similar event.
Amendments that would increase the number of shares reserved for purchase or
that may be purchased by participants during any semi-annual purchase period,
alter the purchase price formula to reduce the purchase price for shares under
the Plans, materially increase the benefits to participants or materially modify
the requirements for participation under the Plans require stockholder approval.
Shares available under the Plans may be either outstanding shares repurchased by
the Company or newly issued shares.
Federal Income Tax Consequences
In general, participants who are citizens or residents of the United States
("U.S. Participants") will not have taxable income or loss under the Plans until
they sell or otherwise dispose of shares acquired under the Plans. If the shares
are held, as of the date of sale or disposition, for longer than both (i) two
years after the beginning of the enrollment period during which the shares were
purchased, and (ii) one year following purchase, a U.S. Participant will have
taxable ordinary income equal to 15% of the fair market value of the shares on
the first day of the enrollment period (but not in excess of the gain on the
sale). Any additional gain from the sale will be long-term capital gain. The
Company is not entitled to an income tax deduction if the holding periods are
satisfied.
If the shares are disposed of within either of the foregoing holding periods
(a "disqualifying disposition"), a U.S. Participant will have taxable ordinary
income equal to the excess of the fair market value of the shares on the
purchase date over the purchase price. In addition, the U.S. Participant will
have taxable capital gain (or loss) measured by the difference between the sale
price and the U.S. Participant's purchase price plus the amount of ordinary
income recognized, which gain (or loss) will be long-term if the shares have
been held, as of the date of sale, for more than one year. The Company is
entitled to an income tax deduction equal to the amount of ordinary income
taxable to a U.S. Participant in a disqualifying disposition.
The consequences to non-U.S. Participants are governed by foreign laws,
which typically do not offer the same tax advantages as United States law.
19
Plan Benefits Table
The following table shows the "Dollar Value" and number of shares purchased
under the Plans by each of the named executive officers and the groups listed
below during fiscal 2002. The "Dollar Value" is the difference between the fair
market value of the stock at the date of purchase and the participant's purchase
price for the stock.
Plan Benefits
Employee Stock Purchase Plan
International Employee Stock Purchase Plan (1)
Number of
Name Shares Dollar
Purchased Value
Aart J. de Geus.............................................. 452 $5,461
Chief Executive Officer and Chairman of the Board
Chi-Foon Chan................................................ 452 $5,461
President and Chief Operating Officer
Vicki L. Andrews............................................. 452 $5,461
Senior Vice President, World Wide Sales
Steven K. Shevick...............................................452 $5,461
Senior Vice President and Chief Financial Officer
Robert B. Henske (2)............................................452 $5,461
Former Senior Vice President and Chief Financial Officer
Executive Officers as a group (6 persons).................... 2,260 $27,304
Non-employee directors as a group............................ -- (3) --
Non-executive officer employees as a group..................625,681(4) $7,106,074
------------
(1) Future benefits or amounts received cannot be calculated as they are
dependent on each individual's decision as to the amount of salary to
be deducted for stock purchases and the stock price in effect at the
time of purchase.
(2) Mr. Henske resigned from his position effective January 3, 2003.
(3) Non-employee directors are not eligible to participate in the Plans.
(4) Represents all employees other than the executive officers of the
Company.
20
PROPOSAL THREE -- RATIFICATION OF APPOINTMENT
OF INDEPENDENT AUDITORS
The Audit Committee has appointed the firm of KPMG LLP, independent
auditors, to audit the financial statements of Synopsys for fiscal 2003. KPMG
LLP has audited Synopsys' consolidated financial statements since fiscal 1992.
Stockholders are being asked to ratify the Audit Committee's selection of KPMG
LLP as independent auditors.
A KPMG LLP representative is expected to be present at the Annual Meeting,
will have the opportunity to make a statement if he or she desires to do so, and
will be available to respond to appropriate questions.
Ratification of the appointment of KPMG LLP requires the affirmative vote of
a majority of the votes cast at a duly held stockholders meeting at which there
is a quorum.
Recommendation
The Board of Directors recommends that the stockholders vote FOR the
ratification of the selection of KPMG to serve as Synopsys' independent auditors
for fiscal 2003.
ADDITIONAL INFORMATION
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors, executive officers
and greater than ten percent beneficial owners of our stock to file reports of
ownership and changes in ownership with the SEC. Directors, executive officers
and greater than ten percent stockholders are required by SEC regulations to
furnish Synopsys with copies of all Section 16(a) reports they file.
Based solely on its review of the copies of the Forms 3, 4 and 5 received
and/or written representations from certain reporting persons, Synopsys believes
that each of its directors, executive officers and greater than ten percent
beneficial owners of its stock during the fiscal 2002 have complied with all
filing requirements applicable to such persons.
Annual Report on Form 10-K
A copy of our Annual Report on Form 10-K for fiscal 2002, as amended, has
been mailed concurrently with this Proxy Statement to all stockholders entitled
to notice of and to vote at the Annual Meeting. The letter to stockholders
attached to the Annual Report is not incorporated into this Proxy Statement and
shall not be considered proxy solicitation material.
Date for Receipt of Stockholder Proposals
We know of no other matters that will be presented for consideration at the
Annual Meeting. If any other matters properly come before the Annual Meeting,
the persons named in the enclosed Proxy intend to vote the shares they represent
as the Board of Directors may recommend. Discretionary authority with respect to
such other matters is granted by the execution of the enclosed Proxy.
Synopsys stockholders who intend to present one or more proposals at our
2004 Annual Meeting of Stockholders, including nominations to the Board of
Directors of persons other than those nominated by the Board, must notify
Synopsys no later than February 9, 2004 in order that they may be timely under
our Bylaws and may be considered for inclusion in the proxy statement and proxy
relating to that meeting; provided that, if the date of our 2004 Annual Meeting
of Stockholders is changed by more than 30 days, such notice must be delivered
to Synopsys a reasonable time before the solicitation is made. A stockholder's
notice to Synopsys must include, with respect to each matter the stockholder
proposes to bring before the annual meeting: (i) a brief description of the
matter and the reasons for conducting such business at the annual meeting, (ii)
the name and address of the stockholder, as they appear on our books, (iii) the
number of shares beneficially owned by the stockholder, (iv) any material
interest of the stockholder in the proposal, and (v) any other information that
is required to be provided by the stockholder pursuant to Regulation 14A under
21
the Exchange Act. Nominations of persons to the Board of Directors must include,
with respect to each nomination and the nominating stockholder, (a) the name,
age, business address and residence address of such person, (b) the principal
occupation or employment of such person, (c) the class and number of shares of
Synopsys which are beneficially owned by such person, (d) a description of all
arrangements or understandings between the stockholder and each nominee and
other person or persons (naming such person or persons) pursuant to which the
nominations are to be made by the stockholder, and (e) any other information
relating to such person that is required to be disclosed in solicitations of
proxies for elections of directors, or is otherwise required under the Exchange
Act.
Notwithstanding the foregoing, the stockholder must also provide notice as
required by the Exchange Act and the applicable regulations thereunder. The
chairman of the Annual Meeting may determine, if the facts warrant, that a
matter has not been properly brought before the meeting and, therefore, may not
be considered at the meeting.
THE BOARD OF DIRECTORS
Dated: May 9, 2003
22
Appendix A
Charter for the Audit Committee of the Board of Directors of Synopsys, Inc.
(revised December 9, 2002)
PURPOSE
The Audit Committee is appointed by the Board of Directors of Synopsys,
Inc. (the "Company") to assist the Board in fulfilling its financial oversight
responsibilities relating to (i) the integrity of the Company's financial
statements and financial reporting process and the Company's systems of internal
accounting and financial controls; (ii) the performance of the internal audit
services function; (iii) the annual independent audit of the Company's financial
statements, the engagement of the independent auditors and the evaluation of the
independent auditors' qualifications, independence and performance; (iv) the
compliance by the Company with legal and regulatory requirements, including the
Company's disclosure controls and procedures; (v) the evaluation of enterprise
risk issues; and (vi) the fulfillment of the other responsibilities set out
herein and as the Board of Directors may from time to time prescribe.
MEMBERSHIP AND MEETINGS
The Audit Committee shall be comprised of three or more directors as
determined by the Board, each of whom shall meet the independence requirements
of the Nasdaq National Market of the National Association of Securities Dealers,
Inc. and the rules of the Securities and Exchange Commission ("SEC") and one of
whom shall be designated by the Board as Chairperson. All members of the Audit
Committee shall have a basic understanding of finance and accounting and be able
to read and understand fundamental financial statements at the time of
appointment. Additionally, at least one member shall have past employment
experience in finance or accounting, requisite professional certification in
accounting, or other comparable experience or background, including a current or
past position as a principal financial officer or other senior officer with
financial oversight responsibilities.
The Audit Committee shall meet at least four times annually.
RESPONSIBILITIES AND DUTIES
Audit/ Internal Controls
1. Meet with the outside auditors and financial management of the Company
to review the scope of the proposed audit for the current year and the
audit procedures to be utilized, and at the conclusion thereof review
such audit, including any comments or recommendations of the outside
auditors.
2. Meet with the representatives of the Company's independent auditors,
both with and without members of management present. Among the items to
be discussed in these meetings are the outside auditors' evaluation of
the Company's financial and accounting personnel and the cooperation
that the outside auditors receive during the course of the audit.
3. Review with the outside auditors and the Company's financial and
accounting personnel the adequacy and effectiveness of the internal
controls of the Company, and elicit any recommendations for the
improvement of such internal control procedures or particular areas
where new or more detailed controls or procedures are desirable.
Particular emphasis should be given to the adequacy of such internal
controls to expose any payments, transactions or procedures that might
be deemed illegal or otherwise improper.
4. The Committee shall review with the independent auditors any problems
or difficulties the auditors may have encountered in connection with
the annual audit or otherwise and any management letter provided by the
auditors and the Company's response to that letter. Such review shall
address any difficulties encountered in the course of the audit work,
including any restrictions on the scope of activities or access to
required information, any disagreements with management regarding
generally accepted accounting principles and other matters, material
adjustments to the financial statements recommended by the independent
auditors and adjustments that were proposed but "passed," regardless of
materiality.
23
5. Oversee the internal audit function of the Company, including
consultation with the internal auditor to determine areas for review
and audit, review of the internal audit group budget and activities of
the internal audit function, review of significant reports prepared by
the internal audit department together with management's response and
follow-up to these reports, and the coordination of the internal audit
program with the independent auditors, with particular attention to the
balance between independent and internal auditing resources. The
Committee shall meet privately with the internal auditor as necessary.
The Committee shall annually review the experience and qualifications
of the senior members of the internal auditors and the quality control
procedures of the internal auditors.
6. Discuss periodically policies for risk assessments and risk management
with members of the Treasury and Internal Audit groups.
Financial Statements
7. Review and discuss with management and outside auditors the press
release and conference call regarding the annual financial statements
and earnings guidance.
8. Review with management and the outside auditors the Company's annual
financial statements. Discuss any significant changes to the Company's
accounting principles and any items required to be communicated by the
independent auditors in accordance with Statement of Accounting
Standards 61. Based on such review and discussion, the Committee shall
make a determination whether to recommend to the Board of Directors
that the audited financial statements be included in the Company's
Annual Report on Form 10-K.
Outside Auditors
9. The Audit Committee shall have the sole authority to approve the hiring
and firing of the independent auditors, all audit engagement fees and
terms and all non-audit engagements, as may be permissible, with the
independent auditors. The Committee shall review the performance of the
Company's independent auditors annually. In doing so, the Committee
shall consult with management and shall obtain and review a report by
the independent auditors describing their internal control procedures,
issues raised by their most recent internal quality control review, or
peer review (if applicable), or by any inquiry or investigation by
governmental or professional authorities for the preceding five years
and the response of the independent auditors. The Committee shall
consider whether it is appropriate to adopt a policy of rotating
independent auditors on a periodic basis.
10. The Audit Committee shall pre-approve audit and non-audit services
provided to the Company by the independent auditors (or subsequently
approve non-audit services in those circumstances where a subsequent
approval is necessary and permissible).
11. Receive from outside auditors annually a formal written statement
delineating all relationships between the outside auditors and the
Company, consistent with the Independence Standards Board Standard 1,
and actively engage in a dialogue with the outside auditors with
respect to any disclosed relationships or services that may affect the
objectivity and independence of the auditors and take or recommend that
the full Board take appropriate action to oversee the independence of
the auditors.
Charter
12. Review and reassess the adequacy of this Charter once each year.
Periodically evaluate the Audit Committee's performance and measure
against best practices.
13. Have this Charter published in the proxy materials relating to Annual
Meetings of Stockholders at least once every three years in accordance
with SEC regulations.
Other Responsibilities
14. The Committee shall review annually a summary of compliance with the
Company's Code of Ethics and Business Conduct.
24
15. The Committee shall approve procedures for the receipt, retention and
treatment of complaints received by the Company regarding accounting,
internal accounting controls or auditing matters and the confidential,
anonymous submission by employees of the Company of concerns regarding
questionable accounting or auditing matters.
16. The Committee shall meet periodically and separately with the General
Counsel and other appropriate legal staff of the Company to review
material legal affairs of the Company and the Company's compliance with
applicable law and listing standards.
17. The Committee shall review periodically with management, the
independent auditors the effect of new or proposed regulatory and
accounting initiatives on the Company's financial statements and other
public disclosures.
18. The Committee shall approve or ratify all transactions between the
Company and an executive officer or director other than (A) grants of
stock options made by the Board or any committee thereof or pursuant to
an automatic grant plan or (B) payment of compensation authorized by
the Board or any committee thereof and shall review periodically, but
no less frequently than annually, a summary of such transactions.
19. Investigate any matter brought to its attention within the scope of its
duties, with the power to retain outside counsel and advisors for this
purpose if, in its judgment, that is appropriate.
20. Annually prepare a report to stockholders as required by the SEC. The
report should be included in the Company's annual proxy statement.
21. Maintain minutes of meetings and submit such minutes to, or review the
matters discussed at each such meeting with, the Board of Directors.
22. Take such other actions as may be necessary or appropriate under the
rules of the SEC or the National Association of Securities Dealers.
COMPENSATION
Members of the Audit Committee shall receive such fees, if any, for
their service as Audit Committee members as may be determined by the Board of
Directors at its sole discretion. Such fees may include retainers or per meeting
fees. Fees may be paid in such form of consideration as is determined by the
Board of Directors.
Members of the Audit Committee may not receive any compensation from
the Company except the fees that they receive for service as a member of the
Board of Directors or any committee thereof.
25
Appendix -B-1
SYNOPSYS, INC.
EMPLOYEE STOCK PURCHASE PLAN
(As amended on August 1, 1999, January 11, 2001,
March 8, 2000, February 28, 2001 and April 24, 2003)
I. PURPOSE
The Synopsys, Inc. Employee Stock Purchase Plan (the "Plan") is
intended to provide Eligible Employees of the Company and one or more of its
Corporate Affiliates with the opportunity to acquire a proprietary interest in
the Company through the periodic application of their payroll deductions to the
purchase of shares of the Company's common stock.
II. DEFINITIONS
For purposes of plan administration, the following terms shall have the
meanings indicated.
Base Salary means all compensation paid as wages, salaries,
commissions, overtime, and bonuses (other than bonuses subject to repayment as a
result of a specified future event), but excluding all of the following items
(even if included in taxable income): reimbursements, car allowances or other
expense allowances, severance pay, fringe benefits (cash and noncash), moving
expenses, deferred compensation, income attributable to stock options,
restricted stock grants, SARs and other equity-related incentive programs, and
welfare benefits.
Code means the Internal Revenue Code of 1986, as amended from time to
time.
Company means Synopsys, Inc., a Delaware corporation, and any corporate
successor to all or substantially all of the assets or voting stock of Synopsys,
Inc. which shall by appropriate action adopt the Plan.
Common Stock means shares of the Company's common stock.
Corporate Stock means shares of the Company's common stock.
Corporate Affiliate means any company which is a parent or subsidiary
corporation of the Company (as determined in accordance with Code Section 424),
including any parent or subsidiary corporation which becomes such after the
Effective Date.
Effective Date means the first day of the initial offering period
scheduled to commence upon the later of (i) February 1, 1992 or (ii) the
effective date of the S-8 Registration Statement covering the share of Common
Stock issuable under the Plan. However, for any Corporate Affiliate which
becomes a participating Company in the Plan after the first day of the initial
offering period, a subsequent Effective Date shall be designated with respect to
participation by its Eligible Employees.
Eligible Employee means any person who is engaged, on a
regularly-scheduled basis of more than twenty (20) hours per week and more than
five (5) months per calendar year, in the rendition of personal services to the
Company or any other Participating Company for earnings considered wages under
Section 3121(a) of the Code.
Enrollment Date has the meaning ascribed to it in Section V.A.
Participant means any Eligible Employee of a Participating Company who
is actively participating in the Plan.
Participating Company means the Company and such Corporate Affiliate or
Affiliates as may be designated from time to time by the Board.
26
Semi-Annual Entry Date means (i) during 1999 and each preceding
calendar year within an offering period in effect under the Plan, the first
business day of May and the first business day of November and (ii) during 2000
and all subsequent calendar years within an offering period under the Plan, the
first business day of March and the first business day of September. The
earliest Semi-Annual Entry Date under the Plan shall be November 2, 1992.
Semi-Annual Period of Participation means each period for which the
Participant actually participates in an offering period in effect under the
Plan. There shall be a maximum of four (4) periods of participation within each
offering period. Except as otherwise designated by the Plan Administrator, each
such period shall commence on the applicable Semi-Annual Entry Date.
Semi-Annual Purchase Date means (i) during 1999 and each preceding year
on which shares of Common Stock are automatically purchased for Participants
under the Plan, the last business day of April and October, and (ii) during 2000
and each subsequent year on which shares of Common Stock are automatically
purchased for Participants under the Plan, the last business day of February and
August.
III. ADMINISTRATION
The Plan shall be administered by the Board of Directors of the Company
or a committee that will satisfy Rule 16b-3 of the Securities and Exchange
Commission, as in effect with respect to the Company from time to time (in
either case, the "Board"). The Board may from time to time select a committee or
persons (the "Plan Administrator") to be responsible for any transactions not
subject to Rule 16b-3. Subject to the express provisions of the Plan, to the
overall supervision of the Board, and to the limitations of Section 423 of the
Code, the Plan Administrator may administer, interpret and amend the Plan in any
manner it believes to be desirable (including amendments to outstanding
options/purchase rights and the designation of a brokerage firm at which
accounts for the holding of shares purchased under the Plan must be established
by each employee desiring to participate in the Plan), and any such
interpretation shall be final and binding on all parties who have an interest in
the Plan; provided, however, that the Plan Administrator may not, without the
approval of the Company's Board, (i) increase the number of shares issuable
under the Plan or the maximum number of shares which may be purchased per
Participant or in the aggregate during any one Semi-Annual Period of
Participation under the Plan, except that the Plan Administrator shall have the
authority, exercisable without such stockholder approval, to effect adjustments
to the extent necessary to reflect changes in the Company's capital structure
pursuant to Section VI.B;(ii) alter the purchase price formula so as to reduce
the purchase price payable for the shares issuable under the Plan; or (iii)
materially increase the benefits accruing to Participants under the Plan or
materially modify the requirements for eligibility to participate in the Plan
IV. OFFERING PERIODS
The Plan shall be implemented in a series of offering periods. Each
offering period shall be of a duration of twenty-four (24) months or less as
designated by the Plan Administrator prior to the start date of any offering
period, except that offering periods that include the Semi-Annual Entry Date on
November 1, 1999 shall be of a duration of twenty-two (22) months. Within each
offering period, there shall be a maximum of four (4) Semi-Annual Periods of
Participation.
V. ELIGIBILITY AND PARTICIPATION
A. Each Eligible Employee will be automatically enrolled in the Plan in
the offering period that begins on the first Semi-Annual Entry Date following
the commencement of employment; thereafter, any Eligible Employee may enroll or
re-enroll in the Plan in the offering period that begins as of any Semi-Annual
Entry Date, or such other days as may be established by the Board from time to
time (each, an "Enrollment Date"). To participate, an Eligible Employee must
complete, sign, and submit to the Company an enrollment form prescribed by the
Plan Administrator. Any enrollment form received by the Company by the 15th day
of the month preceding an Enrollment Date (or by the Enrollment Date in the case
of employees hired after such 15th day), or such other date established by the
Plan Administrator from time to time, will be effective on that Enrollment Date.
Enrollment or re-enrollment by a Participant in the Plan on an Enrollment Date
will constitute the grant by the Company to the Participant of an option to
purchase shares of Common Stock from the Company under the Plan. At the end of
each offering period, each Participant who has not withdrawn from the Plan will
automatically be re-enrolled in the Plan in the offering period that begins on
the Enrollment Date immediately following the date on which the option expires.
Furthermore, except as may otherwise be determined by the Plan Administrator,
each Participant who has not withdrawn from the Plan will automatically be
re-enrolled in the Plan in each offering period that begins on an Enrollment
Date on which the fair market value per share of the Company's Common Stock is
lower than the fair market value per share of the Company's Common Stock on the
Enrollment Date for the offering period in which the Participant is then
enrolled. Notwithstanding anything in the Plan to the contrary, if the fair
27
market value (the "Authorization Date FMV") on the date (the "Authorization
Date") on which additional shares of Common Stock are authorized for issuance
hereunder by the Company's shareholders is higher than the fair market value at
the beginning of any Offering Period that commenced prior to the Authorization
Date, then, with respect to any of such authorized shares available to be issued
on Purchase Dates relating to such Offering Period, the Authorization Date FMV
shall be used instead of the fair market value on the Enrollment Date for the
purposes of the preceding sentence, provided that the Plan Administrator, in its
discretion, may waive application of this sentence with respect to the first
Purchase Date occurring after the Authorization Date.
B. The payroll deduction authorized by the Participant for purposes of
acquiring shares of Common Stock under the Plan may be zero percent (0%) or any
whole multiple of one percent (1%) of the Base Salary paid to the Participant
during each Semi-Annual Period of Participation within the offering period, up
to a maximum of ten percent (10%). The deduction rate so authorized shall
continue in effect for the entire Semi-Annual Period of Participation and for
each successive Semi-Annual Period of Participation unless (i) the Participant
shall change the rate for a subsequent Semi-Annual Period of Participation by
filing the appropriate form with the Plan Administrator prior to the
commencement of that Semi-Annual Period of Participation or (ii) the Participant
shall change the rate within a Semi-Annual Period of Participation by filing the
appropriate form with the Plan Administrator. The new rate shall become
effective as soon as practicable following the filing of such form. A
Participant may not increase or decrease the deduction rate more than once per
Semi-Annual Period of Participation in addition to fixing the rate at the
beginning of the Semi-Annual Period of Participation. Payroll deductions,
however, will automatically cease upon the termination of the Participant's
purchase right in accordance with Article VII below.
C. In no event may any Participant's payroll deductions for any one
Semi-Annual Period of Participation exceed Seven Thousand Five Hundred Dollars
($7,500.00).
VI. STOCK SUBJECT TO PLAN
A. The Common Stock purchasable by Participants under the Plan shall,
solely in the discretion of the Plan Administrator, be made available from
either authorized but unissued shares of the Common Stock or from shares of
Common Stock reacquired by the Company, including shares of Common Stock
purchased on the open market. The total number of shares which may be issued
under the Plan shall not exceed 8,850,000 shares, less any shares sold under the
Synopsys, Inc. International Employee Stock Purchase Plan (subject to adjustment
under Section VI.B below), subject to stockholder approval at the 2003 Annual
Meeting of Stockholders.
B. In the event any change is made to the Company's outstanding Common
Stock by reason of any stock dividend, stock split, combination of shares or
other change affecting such outstanding Common Stock as a class without receipt
of consideration, then appropriate adjustments shall be made by the Plan
Administrator to (i) the class and maximum number of shares issuable over the
term of the Plan, (ii) the class and maximum number of shares purchasable per
Participant during each Semi-Annual Period of Participation, (iii) the class and
maximum number of shares purchasable in the aggregate by all Participants on any
one purchase date under the Plan and (iv) the class and number of shares and the
price per share of the Common Stock subject to each purchase right at the time
outstanding under the Plan. Such adjustments shall be designed to preclude the
dilution or enlargement of rights and benefits under the Plan.
VII. PURCHASE RIGHTS
An Employee who participates in the Plan for a particular offering
period shall have the right to purchase shares of Common Stock, in a series of
successive installments during such offering period, upon the terms and
conditions set forth below and shall execute a purchase agreement embodying such
terms and conditions and such other provisions (not inconsistent with the Plan)
as the Plan Administrator may deem advisable.
Purchase Price. Common Stock shall be issuable on each Semi-Annual
Purchase Date at a purchase price equal to 85 percent of the lower of (i) the
fair market value per share on the Participant's Enrollment Date or (ii) the
fair market value per share on the Semi-Annual Purchase Date. Notwithstanding
anything in the Plan to the contrary, if the Authorization Date FMV is higher
than the fair market value at the beginning of any Offering Period that
commenced prior to the Authorization Date, then, with respect to any of such
authorized shares available to be issued on Purchase Dates relating to such
Offering Period, the Authorization Date FMV shall be used instead of the fair
market value on the Enrollment Date for the purposes of clause (i) of the
preceding sentence, provided that the Plan Administrator, in its discretion, may
waive application of this sentence with respect to the first Purchase Date
occurring after the Authorization Date.
28
Valuation. For purposes of determining the fair market value per share
of Common Stock on any relevant date, the following procedures shall be in
effect:
(i) If such fair market value is to be determined on any date
on or after the date the Common Stock is first registered under Section
12(g) of the Securities Exchange Act of 1934, then the fair market
value shall be the closing selling price on that date, as officially
quoted on the Nasdaq National Market System. If there is no quoted
selling price for such date, then the closing selling price on the next
preceding day for which there does exist such a quotation shall be
determinative of fair market value.
(ii) If such fair market value is to be determined on any date
prior to the time of such Section 12(g) registration of the Common
Stock, then the fair market value of the Common Stock on such date
shall be determined by the Plan Administrator, after taking into
account such factors as the Plan Administrator deems appropriate.
Number of Purchasable Shares. The number of shares purchasable per
Participant on each Semi-Annual Purchase Date shall be the number of whole
shares obtained by dividing the amount collected from the Participant through
payroll deductions during the corresponding Semi-Annual Period of Participation
by the purchase price in effect for the Semi-Annual Purchase Date. However, no
Participant may, during any Semi-Annual Purchase Period, purchase more than
2,000 shares of Common Stock, subject to periodic adjustment under Section VI.B.
Under no circumstances shall purchase rights be granted under the Plan
to any Eligible Employee if such individual would, immediately after the grant,
own (within the meaning of Code Section 424(d)) or hold outstanding options or
other rights to purchase, stock possessing five percent (5%) or more of the
total combined voting power or value of all classes of stock of the Company or
any of its Corporate Affiliates.
Payment. Payment for the Common Stock purchased under the Plan shall be
effected by means of the Participant's authorized payroll deductions. Such
deductions shall begin on the first pay day coincident with or immediately
following the Participant's Enrollment Date and shall (unless sooner terminated
by the Participant) continue through the pay day ending with or immediately
prior to the last day of the offering period.
The amounts so collected shall be credited to the Participant's book
account under the Plan, but no interest shall be paid on the balance from time
to time outstanding in such account. The amounts collected from a Participant
may be commingled with the general assets of the Company and may be used for
general corporate purposes.
Termination of Purchase Right. The following provisions shall govern
the termination of outstanding purchase rights:
(i) A Participant may, at any time prior to the last five (5)
business days of the Semi-Annual Period of Participation, terminate
his/her outstanding purchase right under the Plan by filing the
prescribed notification form with the Plan Administrator. No further
payroll deductions shall be collected from the Participant with respect
to the terminated purchase right, and any payroll deductions collected
for the Semi-Annual Period of Participation in which such termination
occurs shall, at the Participant's election, be immediately refunded or
held for the purchase of shares on the next Semi-Annual Purchase Date.
If no such election is made, then such funds shall be refunded as soon
as possible after the close of such Semi-Annual Period of
Participation.
(ii) The termination of such purchase right shall be
irrevocable, and the Participant may not subsequently rejoin the
offering period for which such terminated purchase right was granted.
In order to resume participation in any subsequent offering period,
such individual must re-enroll in the Plan in accordance with Section
V.A.
(iii) Should a Participant cease to remain an Eligible
Employee while his/her purchase right remains outstanding or should
there otherwise occur a change in such individual's employee status so
that he/she is no longer an Eligible Employee while holding such
purchase right, then such purchase right shall immediately terminate
upon such termination of service or change in status and all sums
previously collected from the Participant during the Semi-Annual Period
29
of Participation in which the purchase right so terminates shall be
promptly refunded to the Participant. However, should the Participant
die or become permanently disabled while in service or should the
Participant cease employment by reason of a leave of absence, then the
Participant (or the person or persons to whom the rights of the
deceased Participant under the Plan are transferred by will or the laws
of inheritance) shall have the election, exercisable up until the end
of the Semi-Annual Period of Participation in which the Participant
dies or becomes permanently disabled or in which the leave of absence
commences, to (i) withdraw all the funds credited to the Participant's
account at the time of his/her cessation of service or at the
commencement of such leave or (ii) have such funds held for the
purchase of shares of Common Stock at the next Semi-Annual Purchase
Date. If no such election is made, then such funds shall automatically
be held for the purchase of shares of Common Stock at the next
Semi-Annual Purchase Date. In no event, however, shall any further
payroll deductions be added to the Participant's account following
his/her cessation of service or the commencement of such leave. Should
the Participant return to active service following a leave of absence,
then his/her payroll deductions under the Plan shall automatically
resume at the rate in effect at the time the leave began, provided such
return to service occurs prior to the end of the offering period in
which such leave began. For purpose of the Plan: (i) the Participant
shall be considered to remain in service for so long as such
Participant remains in the active employ of the Company or one or more
other Participating Companies and (ii) the Participant shall be deemed
to be permanently disabled if he/she is unable to engage in any
substantial gainful employment, by reason of any medically determinable
physical or mental impairment expected to result in death or to be of
continuous duration of at least twelve (12) months.
Stock Purchase. Shares of Common Stock shall automatically be purchased
on behalf of each Participant (other than Participants whose payroll deductions
have previously been refunded or set aside for refund in accordance with the
"Termination of Purchase Right" provisions above) on each Semi-Annual Purchase
Date. The purchase shall be effected by applying each Participant's payroll
deductions for the Semi-Annual Period of Participation ending on such
Semi-Annual Purchase Date of Participation to the purchase of whole shares of
Common Stock (subject to the limitation on the maximum number of purchasable
shares set forth above) at the purchase price in effect for such Semi-Annual
Period of Participation. Any payroll deductions not applied to such purchase (a)
because they are not sufficient to purchase a whole share or (b) by reason of
the limitation on the maximum number of shares purchasable by the Participant
for that Semi-Annual Period of Participation shall be promptly refunded to the
Participant.
Proration of Purchase Rights. Not more than 500,000 shares of Common
Stock, subject to periodic adjustment under Section VI.B, may be purchased in
the aggregate by all Participants on any one Semi-Annual Purchase Date. Should
the total number of shares of Common Stock which are to be purchased pursuant to
outstanding purchase rights on any particular date exceed either (i) the maximum
limitation on the number of shares purchasable in the aggregate on such date or
(ii) the number of shares then available for issuance under the Plan, the Plan
Administrator shall make a pro-rata allocation of the available shares on a
uniform and non-discriminatory basis, and the payroll deductions for each
Participant, to the extent in excess of the aggregate purchase price payable for
the Common Stock pro-rated to such individual, shall be refunded to such
Participant.
Rights as Stockholder. A Participant shall have no stockholder rights
with respect to the shares subject to his/her outstanding purchase right until
the shares are actually purchased on the Participant's behalf in accordance with
the applicable provisions of the Plan. No adjustments shall be made for
dividends, distributions or other rights for which the record date is prior to
the date of such purchase.
Assignability. No purchase right granted under the Plan shall be
assignable or transferable by the Participant other than by will or by the laws
of descent and distribution following the participant's death, and during the
Participant's lifetime the purchase right shall be exercisable only by the
Participant.
Change in Ownership. Should the Company or its stockholders enter into
an agreement to dispose of all or substantially all of the assets or outstanding
capital stock of the Company by means of:
(i) a sale, merger or other reorganization in which the
Company will not be the surviving corporation (other than a
reorganization effected primarily to change the State in which the
Company is incorporated), or
(ii) a reverse merger in which the Company is the surviving
corporation but in which more than fifty percent (50%) of the Company's
outstanding voting stock is transferred to holders different from those
who held the stock immediately prior to the reverse merger, then all
outstanding purchase rights under the Plan shall automatically be
exercised immediately prior to the consummation of such sale, merger,
reorganization or reverse merger by applying the payroll deductions of
each Participant for the Semi-Annual Period of participation in which
such transaction occurs to the purchase of whole shares of Common Stock
at eighty-five percent (85%) of the lower of (i) the fair market value
of the Common Stock on the Participant's Enrollment Date for the
offering period in which such transaction occurs or (ii) the fair
market value of the Common Stock immediately prior to the consummation
of such transaction. However, the applicable share limitations of
Articles VII and VIII shall continue to apply to any such purchase, and
the clause (i) amount above shall not, for any Participant whose
Enrollment Date for the offering period is other than the start date of
such offering period, be less than the fair market value of the Common
Stock on such start date.
30
The Company shall use its best efforts to provide at least ten (10)
days' advance written notice of the occurrence of any such sale, merger,
reorganization or reverse merger, and Participants shall, following the receipt
of such notice, have the right to terminate their outstanding purchase rights in
accordance with the applicable provisions of this Article VII.
VIII. ACCRUAL LIMITATIONS
A. No Participant shall be entitled to accrue rights to acquire Common
Stock pursuant to any purchase right outstanding under this Plan if and to the
extent such accrual, when aggregated with (I) rights to purchase Common Stock
accrued under any other purchase right outstanding under this Plan and (II)
similar rights accrued under other employee stock purchase plans (within the
meaning of Section 423 of the Code) of the Company or its Corporate Affiliates,
would otherwise permit such Participant to purchase more than $25,000 worth of
stock of the Company or any Corporate Affiliate (determined on the basis of the
fair market value of such stock on the date or dates such rights are granted to
the Participant) for each calendar year such rights are at any time outstanding.
B. For purposes of applying such accrual limitations, the right to
acquire Common Stock pursuant to each purchase right outstanding under the Plan
shall accrue as follows:
(i) The right to acquire Common Stock under each such purchase
right shall accrue in a series of successive semi-annual installments
as and when the purchase right first becomes exercisable for each
semi-annual installment on the last business day of each Semi-Annual
Period of Participation for which the right remains outstanding.
(ii) No right to acquire Common Stock under any outstanding
purchase right shall accrue to the extent the Participant has already
accrued in the same calendar year the right to acquire $25,000 worth of
Common Stock (determined on the basis of the fair market value on the
date or dates of grant) pursuant to one or more purchase rights held by
the Participant during such calendar year.
(iii) If by reason of such accrual limitations, any purchase
right of a Participant does not accrue for a particular Semi-Annual
Period of Participation, then the payroll deductions which the
Participant made during that Semi-Annual Period of Participation with
respect to such purchase right shall be promptly refunded.
C. In the event there is any conflict between the provisions of this
Article VIII and one or more provisions of the Plan or any instrument issued
thereunder, the provisions of this Article VIII shall be controlling.
IX. STATUS OF PLAN UNDER FEDERAL TAX LAWS
The Plan is designed to qualify as an employee stock purchase plan
under Code Section 423.
X. AMENDMENT AND TERMINATION
A. The Board may amend, alter, suspend, discontinue, or terminate the
Plan at any time, including amendments to outstanding options/purchase rights.
However, the Board may not, without the approval of the Company's stockholders:
(i) increase the number of shares issuable under the Plan or
the maximum number of shares which may be purchased per Participant or
in the aggregate during any one Semi-Annual Period of Participation
under the Plan, except that the Plan Administrator shall have the
authority, exercisable without such stockholder approval, to effect
adjustments to the extent necessary to reflect changes in the Company's
capital structure pursuant to Section VI.B;
(ii) alter the purchase price formula so as to reduce the
purchase price payable for the shares issuable under the Plan; or
(iii) materially increase the benefits accruing to
Participants under the Plan or materially modify the requirements for
eligibility to participate in the Plan.
31
B. The Board may elect to terminate any or all outstanding purchase
rights at any time. In the event the Plan is terminated, the Board may also
elect to terminate outstanding purchase rights either immediately or upon
completion of the purchase of shares on the next Semi-Annual Purchase Date, or
may elect to permit purchase rights to expire in accordance with their terms
(and participation to continue through such expiration dates). If purchase
rights are terminated prior to expiration, all funds contributed to the Plan
that have not been used to purchase shares shall be returned to the Participants
as soon as administratively feasible.
XI. GENERAL PROVISIONS
A. The Plan shall become effective on the designated Effective Date,
provided that no offering period shall commence, and no shares of Common Stock
shall be issued hereunder, until (i) the Plan shall have been approved by the
stockholders and (ii) the Company shall have complied with all applicable
requirements of the Securities Act of 1933 (as amended), all applicable listing
requirements of any securities exchange on which shares of the Common Stock are
listed and all other applicable requirements established by law or regulation.
In the event such stockholder approval is not obtained, or such Company
compliance is not effected, within twelve (12) months after the date on which
the Plan is adopted by the Board, the Plan shall terminate and have no further
force of effect.
32
Appendix B-2
SYNOPSYS, INC.
INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN
(As amended on August 1, 1999, January 11, 2001,
March 8, 2000, February 28, 2001 and April 24, 2003)
I. PURPOSE
The Synopsys, Inc. International Employee Stock Purchase Plan (the
"Plan") is intended to provide Eligible Employees of designated subsidiaries of
the Company with the opportunity to acquire a proprietary interest in the
Company through the periodic application of their payroll deductions to the
purchase of shares of the Company's common stock.
II. DEFINITIONS
For purposes of plan administration, the following terms shall have the
meanings indicated:
Base Salary means all compensation paid as wages, salaries,
commissions, overtime, and bonuses (other than bonuses subject to repayment as a
result of a specified future event), but excluding all of the following items
(even if included in taxable income): reimbursements, car allowances or other
expense allowances, severance pay, fringe benefits (cash and noncash), moving
expenses, deferred compensation, income attributable to stock options,
restricted stock grants, SARs and other equity-related incentive programs, and
welfare benefits.
Code means the Internal Revenue Code of 1986, as amended from time to
time.
Company means Synopsys, Inc., a Delaware corporation, and any corporate
successor to all or substantially all of the assets or voting stock of Synopsys,
Inc. which shall by appropriate action adopt the Plan.
Common Stock means shares of the Company's common stock.
Corporate Affiliate means any company which is a parent or subsidiary
corporation of the Company (as determined in accordance with Code Section 424),
including any parent or subsidiary corporation which becomes such after the
Effective Date.
Effective Date means the first day of the initial offering period
scheduled to commence on May 3, 1993. However, for any Subsidiary which becomes
a Participating Subsidiary in the Plan after the first day of the initial
offering period, a subsequent Effective Date shall be designated with respect to
participation by its Eligible Employees.
Eligible Employee means any person who is engaged, on a
regularly-scheduled basis of more than twenty (20) hours per week and more than
five (5) months per calendar year, in the rendition of personal services to any
Participating Subsidiary for earnings considered wages under Section 3121(a) of
the Code, but shall not include persons prohibited by the laws of the nation of
their residence or employment from participating in the Plan.
Enrollment Date has the meaning ascribed to it in Section V.A.
Participant means any Eligible Employee of a Participating Subsidiary
who is actively participating in the Plan.
Participating Subsidiary means a Subsidiary of the Company that has
been designated as a Participating Subsidiary by the Board.
33
Semi-Annual Entry Date means (i) during 1999 and each preceding
calendar year within an offering period in effect under the Plan, the first
business day of May and the first business day of November and (ii) during 2000
and all subsequent calendar years within an offering period under the Plan, the
first business day of March and the first business day of September. The
earliest Semi-Annual Entry Date under the Plan shall be May 3, 1993.
Semi-Annual Period of Participation means each period for which the
Participant actually participates in an offering period in effect under the
Plan. There shall be a maximum of four (4) periods of participation within each
offering period. Except as otherwise designated by the Plan Administrator, each
such period shall commence on the applicable Semi-Annual Entry Date.
Semi-Annual Purchase Date means (i) during 1999 and each preceding year
on which shares of Common Stock are automatically purchased for Participants
under the Plan, the last business day of April and October, and (ii) during 2000
and each subsequent year on which shares of Common Stock are automatically
purchased for Participants under the Plan, the last business day of February and
August.
Subsidiary shall mean any corporation described in Section 425(e) or
(f) of the Code.
III. ADMINISTRATION
The Plan shall be administered by the Board of Directors or a committee
that will satisfy Rule 16b-3 of the Securities and Exchange Commission, as in
effect with respect to the Company from time to time (in either case, the
"Board"). The Board may from time to time select a committee or persons (the
"Plan Administrator") to be responsible for any transactions not subject to Rule
16b-3. Subject to the express provisions of the Plan, to the overall supervision
of the Board, and to the limitations of Section 423 of the Code, the Plan
Administrator may administer, interpret and amend the Plan in any manner it
believes to be desirable (including amendments to outstanding options/purchase
rights and the designation of a brokerage firm at which accounts for the holding
of shares purchased under the Plan must be established by each employee desiring
to participate in the Plan), and any such interpretation shall be final and
binding on all parties who have an interest in the Plan; provided, however, that
the Plan Administrator may not, without the approval of the Company's Board, (i)
increase the number of shares issuable under the Plan or the maximum number of
shares which may be purchased per Participant or in the aggregate during any one
Semi-Annual Period of Participation under the Plan, except that the Plan
Administrator shall have the authority, exercisable without such stockholder
approval, to effect adjustments to the extent necessary to reflect changes in
the Company's capital structure pursuant to Section VI.B;(ii) alter the purchase
price formula so as to reduce the purchase price payable for the shares issuable
under the Plan; or (iii) materially increase the benefits accruing to
Participants under the Plan or materially modify the requirements for
eligibility to participate in the Plan
IV. OFFERING PERIODS
The Plan shall be implemented in a series of offering periods. Each
offering period shall be of a duration of twenty-four (24) months or less as
designated by the Plan Administrator prior to the start date of any offering
period, except that offering periods that include the Semi-Annual Entry Date on
November 1, 1999 shall be of a duration of twenty-two (22) months. Within each
offering period, there shall be a maximum of four (4) Semi-Annual Periods of
Participation.
V. ELIGIBILITY AND PARTICIPATION
A. Each Eligible Employee of a Participating Subsidiary shall be
eligible to participate in the Plan in accordance with the following provisions:
- The Board may at any time designate one or more Subsidiaries
as participating in the Plan. The names of all Participating
Subsidiaries shall be shown on Exhibit A to the Plan, which shall be
amended from time to time to reflect additions and deletions of
Participating Subsidiaries; failure to show a Participating Subsidiary
on Exhibit A shall not, however, prevent otherwise eligible employees
of that Subsidiary from participating in the Plan. No Subsidiary
participating in the Company's Employee Stock Purchase Plan effective
May 3, 1993 may be designated for participation in the Plan.
- Each Eligible Employee will be automatically enrolled in the
Plan in the offering period that begins on the first Semi-Annual Entry
Date following the commencement of employment; thereafter, any Eligible
34
Employee may enroll or re-enroll in the Plan in the offering period
that begins as of any Semi-Annual Entry Date, or such other days as may
be established by the Board from time to time (each, an "Enrollment
Date"). To participate, an Eligible Employee must complete, sign, and
submit to the Company an enrollment form prescribed by the Plan
Administrator. Any enrollment form received by the Company by the 15th
day of the month preceding an Enrollment Date (or by the Enrollment
Date in the case of employees hired after such 15th day), or such other
date established by the Plan Administrator from time to time, will be
effective on that Enrollment Date. Enrollment or re-enrollment by a
Participant in the Plan on an Enrollment Date will constitute the grant
by the Company to the Participant of an option to purchase shares of
Common Stock from the Company under the Plan. At the end of each
offering period, each Participant who has not withdrawn from the Plan
will automatically be re-enrolled in the Plan in the offering period
that begins on the Enrollment Date immediately following the date on
which the option expires. Furthermore, except as may otherwise be
determined by the Plan Administrator, each Participant who has not
withdrawn from the Plan will automatically be re-enrolled in the Plan
in each offering period that begins on an Enrollment Date on which the
fair market value per share of the Company's Common Stock is lower than
the fair market value per share of the Company's Common Stock on the
Enrollment Date for the offering period in which the Participant is
then enrolled. Notwithstanding anything in the Plan to the contrary, if
the fair market value (the "Authorization Date FMV") on the date (the
"Authorization Date") on which additional shares of Common Stock are
authorized for issuance hereunder by the Company's shareholders is
higher than the fair market value at the beginning of any Offering
Period that commenced prior to the Authorization Date, then, with
respect to any of such authorized shares available to be issued on
Purchase Dates relating to such Offering Period, the Authorization Date
FMV shall be used instead of the fair market value on the Enrollment
Date for the purposes of the preceding sentence, provided that the Plan
Administrator, in its discretion, may waive application of this
sentence with respect to the first Purchase Date occurring after the
Authorization Date.
- An individual who becomes an Eligible Employee immediately
following termination of such employee's participation in the Synopsys,
Inc. Employee Stock Purchase Plan shall, for purposes of participation
in the Plan, have a deemed Enrollment Date corresponding to such
employee's most recent Enrollment Date under the Synopsys, Inc.
Employee Stock Purchase Plan.
B. The payroll deduction authorized by the Participant for purposes of
acquiring shares of Common Stock under the Plan may be zero percent (0%) or any
whole multiple of one percent (1%) of the Base Salary paid to the Participant
during each Semi-Annual Period of Participation within the offering period, up
to a maximum of ten percent (10%). The deduction rate so authorized shall
continue in effect for the entire Semi-Annual Period of Participation and for
each successive Semi-Annual Period of Participation unless (i) the Participant
shall change the rate for a subsequent Semi-Annual Period of Participation by
filing the appropriate form with the Plan Administrator prior to the
commencement of that Semi-Annual Period of Participation or (ii) the Participant
shall change the rate within a Semi-Annual Period of Participation by filing the
appropriate form with the Plan Administrator. The new rate shall become
effective as soon as practicable following the filing of such form. A
Participant may not increase or decrease the deduction rate more than once per
Semi-Annual Period of Participation in addition to fixing the rate at the
beginning of the Semi-Annual Period of Participation. Payroll deductions,
however, will automatically cease upon the termination of the Participant's
purchase right in accordance with Article VII below.
C. In no event may any Participant's payroll deductions for any one
Semi-Annual Period of Participation exceed Seven Thousand Five Hundred Dollars
($7,500.00) calculated on the Purchase Date following conversion of accumulated
withholdings into U.S. Dollars.
D. It is intended that all eligible employees shall have substantially
equivalent rights and privileges with respect to the Plan; notwithstanding any
other provision of the Plan, however, the Plan Administrator may make such
changes in the terms of eligibility and participation from Subsidiary to
Subsidiary that it determines, in its discretion, to be necessary or desirable
to reflect or comply with local laws or conditions.
VI. STOCK SUBJECT TO PLAN
A. The Common Stock purchasable by Participants under the Plan shall,
solely in the discretion of the Plan Administrator, be made available from
either authorized but unissued shares of the Common Stock or from shares of
Common Stock reacquired by the Company, including shares of Common Stock
purchased on the open market. The total number of shares which may be issued
under the Plan shall not exceed 8,850,000 shares, less any shares sold under the
Synopsys, Inc. Employee Stock Purchase Plan (subject to adjustment under Section
VI.B below), subject to stockholder approval at the 2003 Annual Meeting of
Stockholders
35
B. In the event any change is made to the Company's outstanding Common
Stock by reason of any stock dividend, stock split, combination of shares or
other change affecting such outstanding Common Stock as a class without receipt
of consideration, then appropriate adjustments shall be made by the Plan
Administrator to (i) the class and maximum number of shares issuable over the
term of the Plan, (ii) the class and maximum number of shares purchasable per
Participant during each Semi-Annual Period of Participation, (iii) the class and
maximum number of shares purchasable in the aggregate by all Participants on any
one purchase date under the Plan and (iv) the class and number of shares and the
price per share of the Common Stock subject to each purchase right at the time
outstanding under the Plan. Such adjustments shall be designed to preclude the
dilution or enlargement of rights and benefits under the Plan.
VII. PURCHASE RIGHTS
An Employee who participates in the Plan for a particular offering
period shall have the right to purchase shares of Common Stock, in a series of
successive installments during such offering period, upon the terms and
conditions set forth below and shall execute such agreements and documents
embodying such terms and conditions and such other provisions (not inconsistent
with the Plan) as the Plan Administrator may deem advisable.
Purchase Price. Common Stock shall be issuable on each Semi-Annual
Purchase Date at a purchase price equal to eighty-five percent (85%) of the
lower of (i) the fair market value per share on the Participant's Enrollment
Date or (ii) the fair market value per share on the Semi-Annual Purchase Date.
Notwithstanding anything in the Plan to the contrary, if the Authorization Date
FMV is higher than the fair market value at the beginning of any Offering Period
that commenced prior to the Authorization Date, then, with respect to any of
such authorized shares available to be issued on Purchase Dates relating to such
Offering Period, the Authorization Date FMV shall be used instead of the fair
market value on the Enrollment Date for the purposes of clause (i) of the
preceding sentence, provided that the Plan Administrator, in its discretion, may
waive application of this sentence with respect to the first Purchase Date
occurring after the Authorization Date.
Valuation. The fair market value per share of Common Stock on any
relevant date shall be the closing selling price of the Common Stock on that
date, as officially quoted on the Nasdaq National Market System. If there is no
quoted selling price for such date, then the closing selling price on the next
preceding day for which there does exist such a quotation shall be determinative
of fair market value.
Number of Purchasable Shares. The number of shares purchasable per
Participant on each Semi-Annual Purchase Date shall be the number of whole
shares obtained by dividing the amount collected, after conversion into U.S.
Dollars on the Purchase Date, from the Participant through payroll deductions
during the corresponding Semi-Annual Period of Participation by the purchase
price in effect for the Semi-Annual Purchase Date. However, no Participant may,
during any one Semi-Annual Purchase Period, purchase more than 2,000 shares of
Common Stock, subject to periodic adjustment under Section VI.B.
Under no circumstances shall purchase rights be granted under the Plan
to any Eligible Employee if such individual would, immediately after the grant,
own (within the meaning of Code Section 424(d)) or hold outstanding options or
other rights to purchase, stock possessing five percent (5%) or more of the
total combined voting power or value of all classes of stock of the Company or
any of its Corporate Affiliates.
Payment; Withholding. Payment for the Common Stock purchased under the
Plan shall be effected by means of the Participant's authorized payroll
deductions. Such deductions shall begin on the first pay day coincident with or
immediately following the Participant's Enrollment Date into the offering period
and shall (unless sooner terminated by the Participant) continue through the pay
day ending with or immediately prior to the last day of the offering period. The
amounts so collected shall be credited to the Participant's book account under
the Plan in local currency, but no interest shall be paid on the balance from
time to time outstanding in such account. The amounts collected from a
Participant may be commingled with the general assets of the Company and/or any
Participating Subsidiary and may be used for general corporate purposes. Upon
disposition of shares acquired by exercise of purchase right, the Participant
shall pay, or make provision adequate to the Company and the Participating
Subsidiary for payment of, all federal, state, and other tax (and similar)
withholdings that the Company or the Participating Subsidiary determines, in its
discretion, are required due to the disposition, including any such withholding
that the Company or the Participating Subsidiary determines, in its discretion,
is necessary to allow the Company or the Participating Subsidiary to claim tax
deductions or other benefits in connection with the disposition. A Participant
36
shall make such similar provisions for payment that the Company or the
Participating Subsidiary determines, in its discretion, are required due to the
exercise of purchase right, including such provisions as are necessary to allow
the Company or the Participating Subsidiary to claim tax deductions or other
benefits in connection with the exercise of purchase right.
Termination of Purchase Right. The following provisions shall govern
the termination of outstanding purchase rights:
(i) A Participant may, at any time prior to the last
five (5) business days of the Semi-Annual Period of
Participation, terminate his/her outstanding purchase right
under the Plan by filing the prescribed notification form with
the Plan Administrator. No further payroll deductions shall be
collected from the Participant with respect to the terminated
purchase right, and any payroll deductions collected for the
Semi-Annual Period of Participation in which such termination
occurs shall, at the Participant's election, be immediately
refunded or held for the purchase of shares on the next
Semi-Annual Purchase Date. If no such election is made, then
such funds shall be refunded as soon as possible after the
close of such Semi-Annual Period of Participation.
(ii) The termination of such purchase right shall be
irrevocable, and the Participant may not subsequently rejoin
the offering period for which such terminated purchase right
was granted. In order to resume participation in any
subsequent offering period, such individual must enroll in the
Plan in accordance with Section V.A.
(iii) Should a Participant cease to remain an
Eligible Employee while his/her purchase right remains
outstanding or should there otherwise occur a change in such
individual's employee status so that he/she is no longer an
Eligible Employee while holding such purchase right, then such
purchase right shall immediately terminate upon such
termination of service or change in status and all sums
previously collected from the Participant during the
Semi-Annual Period of Participation in which the purchase
right so terminates shall be promptly refunded to the
Participant. However, should the Participant die or become
permanently disabled while in service or should the
Participant cease employment by reason of a leave of absence,
then the Participant (or the person or persons to whom the
rights of the deceased Participant under the Plan are
transferred by will or the laws of inheritance) shall have the
election, exercisable up until the end of the Semi-Annual
Period of Participation in which the Participant dies or
becomes permanently disabled or in which the leave of absence
commences, to (i) withdraw all the funds credited to the
Participant's account at the time of his/her cessation of
service or at the commencement of such leave or (ii) have such
funds held for the purchase of shares of Common Stock at the
next Semi-Annual Purchase Date. If no such election is made,
then such funds shall automatically be held for the purchase
of shares of Common Stock at the next Semi-Annual Purchase
Date. In no event, however, shall any further payroll
deductions be added to the Participant's account following
his/her cessation of service or the commencement of such
leave; provided, however, that if a Participant's employment
is terminated because of a transfer of employment to the
Company or any subsidiary of the Company other than a
Participating Subsidiary, any outstanding purchase right shall
not terminate until the occurrence of the earlier of (x) the
last Semi-Annual Purchase Date in the offering period or (y)
enrollment of the Participant in the Company's Employee Stock
Purchase Plan. While a purchase right remains outstanding, the
Company or other subsidiary to which the participant is
transferred shall effect payroll deductions authorized by the
Participant and shall remit them to the Participating
Subsidiary that employed the Participant at the time of the
transfer for purposes of acquiring shares of Common Stock
under the Plan. Following approval by the Company and the
Participating Subsidiary, the Participant may, in lieu of
payroll deduction, pay a corresponding amount to the
Participating Subsidiary if such amount is received on or
before the relevant Purchase Date. Should the Participant
return to active service following a leave of absence, then
his/her payroll deductions under the Plan shall automatically
resume at the rate in effect at the time the leave began,
provided such return to service occurs prior to the end of the
offering period in which such leave began. For purpose of the
Plan: (i) the Participant shall be considered to remain in
service for so long as such Participant remains in the active
employ of the Company or one or more other Participating
Subsidiaries and (ii) the Participant shall be deemed to be
permanently disabled if he/she is unable to engage in any
substantial gainful employment, by reason of any medically
determinable physical or mental impairment expected to result
in death or to be of continuous duration of at least twelve
(12) months.
37
Stock Purchase. Shares of Common Stock shall automatically be purchased
on behalf of each Participant (other than Participants whose payroll deductions
have previously been refunded or set aside for refund in accordance with the
Termination of Purchase Right provisions above) on each Semi-Annual Purchase
Date. The purchase shall be effected by applying each Participant's payroll
deductions after conversion to U.S. Dollars for the Semi-Annual Period of
Participation ending on such semiannual Purchase Date to the purchase of whole
shares of Common Stock (subject to the limitation on the maximum number of
purchasable shares as set forth above) at the purchase price in effect for such
Semi-Annual Period of Participation. Any payroll deductions not applied to such
purchase (a) because they are not sufficient to purchase a whole share or (b) by
reason of the limitation on the maximum number of shares purchasable by the
Participant for that Semi-Annual Period of Participation shall be promptly
refunded to the Participant.
Proration of Purchase Rights. Not more than 500,000 shares of Common
Stock, subject to periodic adjustment under Section VI.B, may be purchased in
the aggregate by all participants under the Plan and under the Synopsys, Inc.
Employee Stock Purchase Plan on any one Semi-Annual Purchase Date. Should the
total number of shares of Common Stock which are to be purchased pursuant to
outstanding purchase rights on any particular date exceed either (i) the maximum
limitation on the number of shares purchasable in the aggregate on such date or
(ii) the number of shares then available for issuance under the Plan and the
Synopsys, Inc. Employee Stock Purchase Plan, the Plan Administrator shall make a
pro-rata allocation of the available shares on a uniform and non-discriminatory
basis (including, to the extent practicable vis a vis participants in the
Synopsys, Inc. Employee Stock Purchase Plan) and the payroll deductions for each
Participant, to the extent in excess of the aggregate purchase price payable for
the Common Stock pro-rated to such individual, shall be refunded to such
Participant.
Rights as Stockholder. A Participant shall have no stockholder rights
with respect to the shares subject to his/her outstanding purchase right until
the shares are actually purchased on the Participant's behalf in accordance;
with the applicable provisions of the Plan. No adjustments shall be made for
dividends, distributions, or other rights for which the record date is prior to
the date of such purchase.
Assignability. No purchase right granted under the Plan shall be
assignable or transferable by the Participant other than by will or by the laws
of descent and distribution following the Participant's death, and during the
Participant's lifetime the purchase right shall be exercisable only by the
Participant.
Change in Ownership. Should the Company or its stockholders enter into
an agreement to dispose of all or substantially all of the assets or outstanding
capital stock of the Company by means of:
(i) a sale, merger or other reorganization in which
the Company will not be the surviving corporation (other than
a reorganization effected primarily to change the State in
which the Company is incorporated), or
(ii) a reverse merger in which the Company is the
surviving corporation but in which more than fifty percent
(50%) of the Company's outstanding voting stock is transferred
to holders different from those who held the stock immediately
prior to the reverse merger, then all outstanding purchase
rights under the Plan shall automatically be exercised
immediately prior to the consummation of such sale, merger,
reorganization or reverse merger by applying the payroll
deductions of each Participant, after conversion into U.S.
Dollars on the date of purchase, for the Semi-Annual Period of
Participation in which such transaction occurs to the purchase
of whole shares of Common Stock at eighty-five percent (85%)
of the lower of (i) the fair market value of the Common Stock
on the Participant's Enrollment Date into the offering period
in which such transaction occurs or (ii) the fair market value
of the Common Stock immediately prior to the consummation of
such transaction. However, the applicable share limitations of
Sections VII and VIII shall continue to apply to any such
purchase, and the clause (i) amount above shall not, for any
Participant whose Enrollment Date for the offering period is
other than the start date of such offering period, be less
than the fair market value of the Common Stock on such start
date.
The Company shall use its best efforts to provide at least ten
(10) days' advance written notice of the occurrence of any such sale, merger,
reorganization or reverse merger, and Participants shall, following the receipt
of such notice, have the right to terminate their outstanding purchase rights in
accordance with the applicable provisions of this Article VII.
VIII. ACCRUAL LIMITATIONS
A. No Participant shall be entitled to accrue rights to acquire Common
Stock pursuant to any purchase right outstanding under this Plan if and to the
38
extent such accrual, when aggregated with (i) rights to purchase Common Stock
accrued under any other purchase right outstanding under this Plan and (ii)
similar rights accrued under other employee stock purchase plans (within the
meaning of Section 423 of the Code) of the Company and its Corporate Affiliates
would otherwise permit such Participant to purchase more than $25,000 worth of
stock of the Company or any Corporate Affiliate (determined on the basis of the
fair market value of such stock on the date or dates such rights are granted to
the Participant) for each calendar year such rights are at any time outstanding.
B. For purposes of applying such accrual limitations, the right to
acquire Common Stock pursuant to each purchase right outstanding under the Plan
shall accrue as follows:
(i) The right to acquire Common Stock under each such
purchase right shall accrue in a series of successive
semi-annual installments as and when the purchase right first
becomes exercisable for each semi-annual installment on the
last business day of each Semi-Annual Period of Participation
for which the right remains outstanding.
(ii) No right to acquire Common Stock under any
outstanding purchase right shall accrue to the extent the
Participant has already accrued in the same calendar year the
right to acquire $25,000 worth of Common Stock (determined on
the basis of the fair market value on the date or dates of
grant) pursuant to one or more purchase rights held by the
Participant during such calendar year.
(iii) If by reason of such accrual limitations, any
purchase right of a Participant does not accrue for a
particular Semi-Annual Period of Participation, then the
payroll deductions which the Participant made during that
Semi-Annual Period of Participation with respect to such
purchase right shall be promptly refunded.
C. In the event there is any conflict between the provisions of this
Section VIII and one or more provisions of the Plan or any instrument issued
thereunder, the provisions of this Section VIII shall be controlling.
IX. AMENDMENT AND TERMINATION
A. The Board may amend, alter, suspend, discontinue, or terminate the
Plan at any time, including amendments to outstanding options/purchase rights.
However, the Board may not, without the approval of the Company's stockholders:
(i) increase the number of shares issuable under the
Plan or the maximum number of shares which may be purchased
per Participant or in the aggregate during any one Semi-Annual
Period of Participation under the Plan, except that the Plan
Administrator shall have the authority, exercisable without
such stockholder approval, to effect adjustments to the extent
necessary to reflect changes in the Company's capital
structure pursuant to Section VI.B;
(ii) alter the purchase price formula so as to reduce
the purchase price payable for the shares issuable under the
Plan; or
(iii) materially increase the benefits accruing to
Participants under the Plan or materially modify the
requirements for eligibility to participate in the Plan.
B. The Board may elect to terminate any or all outstanding purchase
rights at any time. In the event the Plan is terminated, the Board may also
elect to terminate outstanding purchase rights either immediately or upon
completion of the purchase of shares on the next Semi-Annual Purchase Date, or
may elect to permit purchase rights to expire in accordance with their terms
(and participation to continue through such expiration dates). If purchase
rights are terminated prior to expiration, all funds contributed to the Plan
that have not been used to purchase shares shall be returned to the Participants
as soon as administratively feasible.
X. GENERAL PROVISIONS
A. The Plan shall become effective on the date on which it is adopted
by the Board, provided the Company has complied with all applicable requirements
established by law or regulation.
39
B. All costs and expenses incurred in the administration of the Plan
shall be paid by the Company.
C. Neither the action of the Company in establishing the Plan, nor any
action taken under the Plan by the Board or the Plan Administrator, nor any
provision of the Plan itself shall be construed so as to grant any person the
right to remain in the employ of the Company or any of its Corporate Affiliates
for any period of specific duration, and such person's employment may be
terminated at any time, with or without cause.
D. The provisions of the Plan shall be governed by the laws of the
State of California without resort to that State's conflict-of-laws rules.
E. If the Plan Administrator in its discretion so elects, it may retain
a brokerage firm, bank, or other financial institution to assist in the purchase
of shares, delivery of reports, or other administrative aspects of the Plan. If
the Plan Administrator so elects, each Participant shall (unless prohibited by
the laws of the nation of his or her employment or residence) be deemed upon
enrollment in the Plan to have authorized the establishment of an account on his
or her behalf at such institution. Shares purchased by a Participant under the
Plan shall be held in the account in the name in which the share certificate
would otherwise be issued pursuant to Section VII.
40
Schedule A
Companies Participating in
International Employee Stock Purchase
Plan
Name Jurisdiction of Incorporation
---- -----------------------------
Avant! Software & Development Centre
(India) Private Limited India
InSilicon Canada Corporation Canada
InSilicon Canada Holdings ULC Canada
InSilicon Canada Ltd. Canada
Nihon Synopsys KK Japan
Numerical Technologies Canada Inc. Canada
Synopsys Denmark ApS Denmark
Numerical Nova Scotia Company Canada
Numerical Subwavelength Technologies BV Netherlands
Synopsys SARL France
Synopsys Finland OY Finland
Synopsys GmbH Germany
Synopsys (India) Private Ltd. India
Synopsys (India) EDA Software Private Limited India
Synopsys International Limited Ireland
Synopsys Ireland Limited Ireland
Synopsys Ireland Resources Ireland
Synopsys Israel Limited Israel
Synopsys Italia, SRL Italy
Synopsys Korea, Inc. Korea
Synopsys (Northern Europe) Ltd. United Kingdom
Synopsys Scandinavia AB Sweden
Synopsys Singapore Pte. Ltd. Singapore
Synopsys Taiwan Limited Taiwan
41
[PROXY CARD: FRONT SIDE]
SYNOPSYS, INC.
ANNUAL MEETING OF STOCKHOLDERS
THIS PROXY IS SOLICITED ON BEHALF OF THE SYNOPSYS, INC. ("SYNOPSYS") BOARD OF
DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS ON JUNE 20, 2003.
The undersigned revokes all previous proxies, acknowledges receipt of
the Notice of Annual Meeting of Stockholders to be held June 20, 2003, the Proxy
Statement, Letter to Stockholders and Annual Report on Form 10-K for fiscal
2002, and appoints Chi-Foon Chan and Steven K. Shevick, and each of them
individually, the proxy of the undersigned, each with full power of
substitution, to vote all Synopsys common shares that the undersigned is
entitled to vote, either on his or her own behalf or on behalf of any entity or
entities, at the Synopsys annual meeting of stockholders to be held in the
Babbage conference room of Synopsys' offices located at 455 N. Mary Avenue,
Sunnyvale, California on Friday, June 20, 2003 at 4:00 p.m. local time, and at
any adjournment or postponement thereof, with the same force and effect as the
undersigned might or could do if personally present. The shares represented by
the proxy shall be voted in the manner as set forth on the reverse side.
(CONTINUED AND TO BE SIGNED ON REVERSE SIDE)
42
[PROXY CARD: REVERSE SIDE]
YOUR VOTE IS IMPORTANT!
--------------------------------------------------------------------------------
SYNOPSYS, INC.
THE SYNOPSYS BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE PROPOSALS
LISTED BELOW. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS SPECIFIED
BELOW. IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF
THE DIRECTORS LISTED BELOW, FOR APPROVAL OF AN INCREASE IN SHARES IN THE
EMPLOYEE STOCK PURCHASE PLANS, FOR THE RATIFICATION OF THE APPOINTMENT OF KPMG
LLP AND IN THE PROXY HOLDERS' DISCRETION AS TO ANY OTHER MATTERS THAT MAY
PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF.
PLEASE MARK VOTE IN OVAL IN THE FOLLOWING MANNER USING DARK INK ONLY. [ ]
1. Proposal to elect nine directors to serve for the ensuing year or until
their successors are elected. Nominees: 01-Aart J. de Geus, 02-Andy D.
Bryant, 03-Chi-Foon Chan, 04-Bruce R. Chizen, 05-Deborah Coleman, 06-A.
Richard Newton, 07-Sasson Somekh, 08-Roy Vallee and 09-Steven C. Walske
For All Withhold All For All Except*
[ ] [ ] [ ]
-------------------------
*For all nominees except as noted above
2. Proposal to approve an amendment to the Company's Employee Stock Purchase
Plan and International Employee Stock Purchase Plan to increase the number
of shares reserved for issuance thereunder by 1,800,000 shares.
3. Proposal to ratify the appointment of KPMG LLP as independent auditors of
Synopsys for fiscal 2003.
For Against Abstain
[ ] [ ] [ ]
To transact such other business as may properly come before the meeting or any
adjournment or postponement thereof.
Mark here for address change and note above. [ ]
Control number
Signature(s): __________________________ Dated: ___________________, 2003
__________________________ Dated: ___________________, 2003
Please sign exactly as name appears hereon. When shares are held by joint
tenants, both should sign. When signing as an attorney, executor, administrator,
trustee or guardian, please give full title as such. If a corporation, please
sign in full corporate name by the President or other authorized officer. If a
partnership, please sign in partnership name by an authorized person.
--------------------------------------------------------------------------------
FOLD AND DETACH HERE
YOUR VOTE IS IMPORTANT!
PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE
ENCLOSED ENVELOPE. NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED STATES.
43